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ABSTRACT 
Yuan Cheng 
Structural and Functional Studies of E. coli Conjugative Relaxase-Helicase TraI 
and Arabidopsis thaliana Protein Arginine Methyltransferase 10 (PRMT10) 
 (Under the direction of Professor Matthew Redinbo) 
 
TraI, a bifunctional enzyme containing relaxase and helicase activities, initiates and 
drives the conjugative transfer of the E. coli F plasmid. In this work, we investigated the 
function of the putative RecD-like domain of TraI (284-821). We established that TraI 284-
821 can bind nucleotides, but only retained residual ATPase activity likely due to the loss of 
critical catalytic motifs. We also examined the DNA binding properties of the TraI helicase. 
We showed that TraI binds to single-stranded DNA (ssDNA) with a site-size of 
approximately 25 nucleotides and low cooperativity. A double-stranded DNA (dsDNA) 
binding site was identified within the N-terminal region of TraI (1-858), outside the core 
helicase motifs of TraI. We further characterized the impacts of ionic strength, nucleotide 
binding and base composition on TraI-DNA interaction. Finally, we elucidated the solution 
structure of TraI using small-angle x-ray scattering. Taken together, these data resulted in the 
assembly of a model for TraI’s multi-domain helicase activity. 
Protein arginine methyltransferase 10 (PRMT10) regulates flowering-time in 
Arabidposis thaliana. Here, we present the 2.6 Å resolution crystal structure of PRMT10 that 
reveals significant structural features unique to PRMT10, including a long dimerization arm 
and distinct accessibility to the active site. Our data also showed that the N-terminal thirty 
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residues of PRMT10 impact substrate specificity, and that PRMT10 activity was dependent 
on the sequences distal from the substrate methylation site. We further established that 
PRMT10 dimerization is required for activity and used structure-based molecular dynamics 
to indicate how dimerization affects functionally-essential PRMT10 domain motions. Taken 
together, our results provide substantial insights into the mechanism governing the unique 
enzymatic function and substrate specificity of PRMT10.   
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Chapter 1.  Structural and functional studies of multi-domain F Plasmid TraI relaxse-
Helicase 
(This chapter has been published as Cheng Y et al. 2011, J Bio Chem, Feb 2) 
1.1 Introduction 
Conjugative plasmid transfer (CPT) is a central mechanism for the horizontal 
exchange of genetic material between bacterial cells, as well as for the spread of antibiotic 
resistance genes and virulence factors (1-4). CPT requires both a DNA relaxase and a DNA 
helicase. The relaxase initiates DNA transfer by cleaving the transferred strand at a specific 
site within the oriT, forming a 5’ phosphotyrosine intermediate. Following nicking, the 
helicase uses the energy from ATP hydrolysis to unwind the plasmid and drive the transfer of 
DNA into the recipient cell. The relaxase completes plasmid transfer by breaking the 
covalent phosphotyrosine linkage and releasing the transferred DNA for replication in the 
recipient (5-7).  
The relaxase and helicase activities necessary for F plasmid transfer are mediated by 
a 190-kDa multi-domain protein, TraI (8, 9). TraI requires the assistance of a two additional 
F plasmid-encoded proteins, TraY and TraM, as well as Integration Host Factor (IHF) for 
conjugative transfer. These four proteins bind to the 500 bp oriT site and form a protein 
complex called the relaxosome (5). TraI contains three major functional domains, including 
the N-terminal relaxase domain (residue 1-309), a central helicase domain (residues 310-
1476) and a C-terminal domain (CTD, residues 1477-1756) that is responsible for 
interactions with TraY and TraM (10-13). The region between residues 310-
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950 is not fully characterized, although recent work from Schildbach et al suggested that it 
may encode a RecD-like domain (14). The covalent linkage between these functional 
domains is required for efficient conjugation (15).  
TraI is a superfamily I helicase with ssDNA-dependent NTPase and helicase 
activities (16, 17). The translocation of TraI along DNA has 5’ to 3’ polarity (18, 19). TraI 
requires a 5’ single-stranded overhang for the initiation of DNA unwinding (18). In addition, 
TraI functions as a highly processive helicase as a monomer (17). Unlike other helicases, the 
processivity of TraI helicase requires neither oligomerization nor the presence of a 
processivity factor. The underlying mechanism of TraI’s processivity has remained unclear 
(17). 
While the interaction of TraI with DNA is essential to its helicase activity, little is 
known about the DNA-binding properties of the TraI helicase. Matson et al. showed that 
deletion of the region 309-349 disrupts helicase-associated ssDNA binding and the helicase 
activity (10). Recent work from Schildbach et al. suggested that the N-terminal region of 
TraI helicase (residues 303-844) is important for its interaction with ssDNA (14). Numerous 
fundamental aspects of the interaction of the TraI helicase with DNA, such as the length of 
DNA bound by TraI, the intrinsic binding affinity, binding cooperativity, dependence of 
affinity on ionic strength, nucleotide binding, and base specificity, are still unclear. This 
knowledge is important for the quantitative understanding of the interaction between TraI 
helicase and DNA, as well as the molecular mechanism and regulation of TraI helicase 
activity. 
Here, we examined the function of the putative RecD-like domain. Our results show 
that TraI 284-821 can bind nucleotides, but only retains residual ATPase activity likely due 
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to the loss of critical catalytic motifs. We used fluorescence anisotropy-based equilibrium 
binding assays to investigate TraI helicase-associated DNA binding properties. Our studies 
have elucidated the intrinsic binding affinity, binding cooperativity, and the lengths of 
ssDNA and dsDNA bound by TraI. Also, we identified the location of the dsDNA binding 
site within TraI. Furthermore, we investigated the impacts of ionic strength, nucleotide 
binding and base composition on the affinity of TraI for DNA. Finally, we examined the 
spatial organization of TraI domains in solution. Together, these results advance our 
understanding of the interaction between TraI helicase and DNA, providing insights into the 
molecular mechanism by which TraI performs its helicase function. 
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1.2 Materials and methods 
DNA oligomers.   
DNA oligomers used in this study were purchased from Integrated DNA Technology 
(IDT, Coralville, IA).  Labeled oligomers have the fluorescent probe 6-FAM
TM
 covalently 
attached to their 5’ end and were purified using HPLC by IDT. Unlabeled oligomers were 
desalted without further purification. The sequences of DNA oligomers are listed in Table 
1.1. All DNA oligomers were dissolved in oligomer annealing buffer containing 50 mM Tris-
HCl pH 8.0, 50 mM NaCl and 5 mM MgCl2. To prepare duplex DNA, two complementary 
DNA oligomers were mixed in a 1:1 molar ratio, heated to 95
 o
C and slowly cooled down to 
20 
o
C with a speed of 1
 o
C/ min in a thermocycler.  
 
DNA binding buffers.  
Standard DNA binding buffer contained 25 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 
mM Mg acetate and 0.1% BSA. Buffer A contained 25 mM Tris-HCl pH 7.5, 50 mM NaCl, 
5 mM Mg Acetate and 0.1% BSA. Buffer B contained 50 mM Tris-HCl pH 7.5, 100 mM 
NaCl, 5 mM Mg Acetate and 0.1% BSA. Buffer C contained 25 mM Tris-HCl pH 7.5 and 
0.1% BSA. 
 
Protein constructs, expression and purification 
 Standard ligation independent cloning techniques, as described by Stols et al., were 
employed in the construction of expression plasmids encoding the segments of TraI used in 
this study. (20). The amplified DNA fragments were treated and cloned into empty 
pMCSG7-Lic-MBP expression vector. The 6-His MBP tag was cleaved off after purification 
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using tobacco etch virus (TEV) protease. All expression plasmids used in this study were 
sequence verified. 
The expression plasmids were transformed into Escherichia coli BL21 (DE3) Gold 
(Stratagene). Bacteria were grown in LB medium supplemented with 50 μg/ml ampicilin at 
37 
o
C with shaking. After the OD600 reached 0.6, isopropyl β-D-thiogalactoside was added to 
a final concentration of 0.2 mM and bacteria were grown for another 12 hours at 16 
o
C with 
shaking.  Bacteria were harvested and resuspended in loading buffer (50 mM sodium 
phosphate pH 7.6, 500 mM NaCl, 25 mM imidazole) supplemented with 0.5 mM EDTA, 
0.1% Triton X-100, 1 mM PMSF, one tablet of a protease inhibitor cocktail (Roche) and 1 
mg/ml lysozyme. After 1 hour of incubation on ice, the resuspended cells were sonicated on 
ice for 2 min and the lysate was centrifuged at 45,000 × g for 90 min at 4 
o
C. The supernatant 
was passed through a 0.2 μm filter (Millipore) and then loaded onto a 5 ml high performance 
HisTrap
TM
 column (GE Life Sciences), equilibrated with loading buffer. The column was 
washed with 100 ml loading buffer before bound protein was eluted with elution buffer (50 
mM sodium phosphate pH 7.6, 500 mM NaCl, 500 mM imidazole). The eluted protein was 
pooled and loaded onto a HiPrep
TM
 26/10 desalting column (GE Life Sciences) equilibrated 
with desalting buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM DTT and 0.5 mM 
EDTA). Fractions containing protein were collected. TEV protease was added to the pooled 
protein fractions with a ratio of 1:100 (w/w) TEV to TraI. After 16 hours of incubation at 4 
o
C, the mixture was reloaded onto a 5 ml HisTrap
TM
 column equilibrated with loading buffer. 
The flow-through fractions were collected and concentrated in a Centricon YM30 (Amicon) 
concentrator. Finally, concentrated protein was loaded on a HiLoad
TM
 16/60 Superdex 200 
column (GE Life Sciences) equilibrated with sizing buffer (20 mM Tris-HCl pH 7.5, 100 
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mM NaCl, 5% Glycerol). Protein containing fractions were concentrated, flash frozen in 
liquid nitrogen and stored at -80 
o
C.  Purified protein was >95% pure by SDS-PAGE.   
 
TNP-ATP binding assay 
The binding of TNP-ATP to TraI was measured at 22 
o
C
 
in spectrofluorometer SPEX 
Fluorolog 2 as described by weber et al. with some modifications (21). The binding buffer 
contains 20 mM Tris-HCl (pH 7.5) and 20 mM NaCl. Indicated concentrations of TraI were 
titrated with TNP-ATP at a step of 2μl and the samples were equilibrated for 5 min before 
each measurement. The titration was monitored at λexc= 410 nm, λem=547 nm. The slits for 
excitation and emission were set to 2 nm and 5 nm respectively. All measured data points 
were corrected for the dilution and the inner filter effects of TNP-ATP using equation 1 
0.5( / )10 cli oobsdF F V V
    (1) 
where F and Fobsd represent the corrected and measured fluorescence intensities in arbitrary 
units; Vi and Vo represent the volume of the sample after the ith titration and the volume of 
the sample before any titration; ε is the molar absorption of TNP-ATP at the wavelength of 
410 nm, c is the concentration of TNP-ATP in the sample, and l is the length of the light path 
(0.4 cm). Vi /Vo and 10
0.5 εcl 
serve to correct the dilution and inner filter effects respectively. 
 
NADH-coupled NTPase assay 
The NTPase activity of TraI was measured by the NADH-coupled NTPase assay as 
described by Kiianitsa et al. (22). In this assay, the ADP produced from the hydrolysis of 
ATP can be regenerated by the enzyme pyruvate kinase (PK) using phosphoenolpyruvate 
(PEP) as the substrate. The resulting pyruvate is subsequently converted to lactate by L-
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lactate dehydrogenase (LDH) at the expense of the oxidation of NADH, NADH, but not its 
product NAD, has a strong absorbance at 340 nm. Consequently, the hydrolysis of ATP by 
TraI can be monitored by measuring the decline of absorbance at 340 nm. The reaction 
mixture (75 μl) contains 50 mM Tris-HCl (pH 7.5), 10 mM  MgAcO,  600 μM NADH, 25 
mM NaCl, 25 mM K2SO4, 0.1% BSA, 700 μM PEP,  3 unit PK and 3.6 unit LDH (Sigma), 
40 nM ssDNA M13MP18, 1 μM TraI 284-821. The reaction mixture was added into a 96-
well microplate (Corning Inc., NY), and the reaction was triggered by adding indicated 
concentrations of NTP into the reaction mixture. The absorbance at 340 nm was monitored 
for 30 min using Pherastar (BMG Labtech, Offenburg, Germany).        
 
Small angle X-ray scattering (SAXS) and data analysis 
SAXS data was collected for protein solutions and their matched buffers using the 
standard SAXS instrument at the beamline 18-ID (Bio-CAT, Advanced Photon Source, 
Argonne, IL). The experiments were carried out at 16 
o
C using an X-ray photon energy of 12 
keV. The Mar165 CCD detector with an active area of approximately 160 × 80 mm
2 
was 
used for data collection. The sample-to-detector distances were set to 2.3 m to make 
scattering vectors, q, range from 0.007 to 0.38 Å
-1
. The scattering vector here is defined as q 
= 4πsinθ/λ, where 2θ is the scattering angle. Samples were flowed back and forth during 
SAXS measurements with a Hamilton programmable syringe pump to minimize radiation 
damage. Twenty frames of short exposure (2 seconds) were taken on each sample and 
averaged to improve the signal/noise ratio. Data were reduced using Bio-CAT SAXS data 
reduction macros installed in the program Igor (WaveMetrics, Portland, OR). Guinier plots, 
made using the program Igor, were used for detection of aggregation in protein samples. 
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Guinier approximation I(q) = I(0) exp(-q
2
RG
2
/3) with the limits qRg < 1.3 was used to 
determine the radius of gyration, Rg ,and the scattering intensity extrapolated to zero angle 
I(0). The molecular weight of TraI was determined from I(0) on a relative scale using 
cytochrome c as a reference. The pair distribution function, P(r), and the maximum 
dimension of the protein, Dmax, was computed by the program GNOM (23).  
 
Ab initio shape restoration and structural modeling 
The low-resolution shape of TraI was restored from the experimental SAXS profile 
using the program DAMMIN (24). The data within the q range of 0.0104 to 0.2129 Å
-1
 were 
used for the analysis. Forty individual models were generated by DAMMIN (25). The twenty 
models with the best χ2 were aligned using SUBCOMB and averaged using DAMMAVER 
(25). The averaged model was then filtered based on occupancy and volume using 
DAMFILT to generate the final model of TraI. The volumetric representation of the SAXS 
model was prepared by SITUS (26).  
Crystal structures of the relaxase domain (1-307) and the C-terminal domain (1476-
1628) were obtained from Protein Data Bank (PDB) using the accession numbers 1P4B and 
3FLD, respectively.  Homology models of TraI 309-842 and 846-1473 were constructed by 
PHYRE (27) using the crystal structure of RecD from E.coli RecBCD complex (PDB 
accession number 1W36) as a template. The atomic models were placed into the ab initio 
shape by visual judgment using the program Chimera (28). The scattering intensities of the 
structural model were calculated using CRYSOL (29). The goodness of the structural model 
was assessed by CRYSOL based on the discrepancy (χ2) between the calculated scattering 
intensities and the experimental scattering intensities. The orientation and position of 
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individual domains in the structural model were manually adjusted to minimize the 
discrepancy.    
 
Direct DNA binding assays 
Fluorescence anisotropy (FA) based DNA binding assays were employed to study 
DNA binding by TraI as described by Shildbach et al. (30) with some modifications. To 
perform the direct DNA binding assay, a 6FAM-labeled DNA oligomer was mixed with 
increasing concentrations of protein in DNA binding buffer in 384 well plates (Corning Inc., 
NY). The fluorescence anisotropy of each well was measured by a Pherastar plate reader 
(BMG Labtech, Offenburg, Germany) using the excitation and emission wavelengths of 485 
nm and 520 nm, respectively. The fluorescence anisotropy (FA) was defined as  
( ) /( 2 )vv vh vv vhFA I I I I                 (2)  
Where Ivv and Ivh represent the fluorescence intensity signal parallel and perpendicular to the 
excitation polarization. All experiments were done in triplicate. To calculate the macroscopic 
DNA binding constant (KN), normalized data were plotted as average FA vs. total protein 
concentration and fit to equation 2:     
min max min
2
( ) ( ) 4
( )
2
1 1
T T T
N N
T
D x D x D x
K K
FA FA FA FA
D
     
  
 
 
 
 
 
 
 
           (3)              
using nonlinear regression in SigmaPlot 11.0 (Systat Software, Inc.), where FA, observed FA 
signal; FAmin, FA signal in the absence of protein; FAmax, FA signal in the presence of 
saturating concentration of protein; DT, total concentration of 6FAM-labeled DNA; x, total 
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protein concentration; KN, the macroscopic binding constant. The error bars represent the 
standard deviation of three replicates.  
 
The macromolecule titration competition (MCT) method 
The binding of TraI to unlabeled DNA oligomers was investigated using the 
macromolecular competition titration (MCT) method as describe by Bujalowski et al.(31). In 
brief, a 6FAM-labeled reference DNA oligomer (total concentration, DTR) was mixed with 
increasing concentration of protein in DNA binding buffer in 384 well plates in the presence 
of a competing unlabeled DNA oligomer (total concentration, DTS). The fluorescence 
anisotropy of each well was measured using a Pherastar plate reader with the excitation and 
emission wavelengths of 485 nm and 520 nm, respectively.  The total protein concentration 
in the presence of a competing DNA oligomer, PT1, was defined as equation 4 
   1T i TR i TS FR SP D D P                (4) 
Where ( )Ri , ( )si , and PF represent the binding density of the protein on the fluorescent 
DNA oligomer, the binding density on the unlabeled competing DNA oligomer, and the free 
protein concentration, respectively.  In the absence of a competing DNA oligomer, equation 
4 can be simplified as  
 T i T R FRP D P           (5) 
When the same FA signal is observed in the absence and in the presence of a competing 
DNA oligomer, the binding density of the protein on the unlabeled competing DNA 
oligomer, defined as equation 6, can be derived by solving the set of equation (4) and (5).  
  1T Ti S
T S
P P
D

         (6) 
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When  ( )i s  is known, PF can be obtained by using equation 7: 
   1F T i TS i TRS RP P D D            (7)  
The binding stoichiometry is equal to the value of ( )i s when FA reaches its maximum, as 
determined from the plot of  FA versus ( )i s . 
 
Determination of the binding parameter           
The model-independent and thermodynamically rigorous binding isotherm can then 
be constructed by plotting ( )i s  
against PF. The binding isotherms were analyzed using 
Epstein combinatorial approach for binding of a protein to a linear nucleic acid (32).  The 
relation between ( )i  and PF, can be expressed as equation 8 and 9: 
 
1
int
1 0
1
int
0 0
( , )( )
( , )( )
g k
k j
N F
k j
i g k
k j
N F
k j
kP k j K P
P k j K P



 

 
 
 
 
          (8) 
( 1)!( 1)!
( , )
( 1)!( )! !( 1)!
N
N mk k
P k j
N mk k j k j j k j
  

      
      (9) 
Where k is the number of protein bound per nucleic acid, g is the maxium number of k, N is 
the total length of the nucleic acid, m is the size of nucleic acid binding site, Kint is the 
intrinsic binding constant, ω is the cooperativity parameter and j is the number of cooperative 
contacts formed between protein molecules bound to the nucleic acid. The combinatorial 
factor PN (k, j) defines the number of distinct ways that k protein molecules, each of which 
form j cooperative contacts, can bind to a nucleic acid.   
When the nucleic acid can maximally bind one protein molecule, equation 7 and 8 
can be simplified as equation 10 or 11: 
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Competition binding assay  
A 6FAM-labeled DNA oligomer was used as the reference DNA. Protein was mixed 
with the reference DNA and titrated with increasing concentration of a unlabeled DNA 
oligomer (the competitor DNA).  The decrease in fluorescence anisotropy values with the 
titration of the competitor DNA was monitored. The IC50, or the concentration of competitor 
DNA required to displace 50% of the complex formed by protein and reference DNA, was 
determined by plotting the anisotropy value as a function of competitor DNA concentration 
and fitting the curve using equation 12: 
50
max min
min (logIC )
1 10
x
FA FA
FA FA


 

                      (12) 
 
 
 
 
 
 
 13 
 
1.3 Results 
Nucleotide binding to TraI 284-821. 
TraI 284-821 has been suggested to have a protein fold similar to that of the RecD 
helicase from the E.coli RecBCD complex (33). However, if TraI 284-821 can function as a 
RecD helicase has remained unknown. Here we examined the nucleotide binding capacity of 
TraI 284-821 by measuring its interaction with TNP-ATP as described in the materials and 
methods (Figure 1.1). TNP-ATP, a fluorophore-labeled ATP analog, has been commonly 
used in the study of protein-nucleotide interactions (21). Binding of TNP-ATP to a 
nucleotide binding site is often accompanied with an increase in TNP-ATP fluorescence, 
which can be used to monitor the binding process. Our results show that TNP-ATP can bind 
tightly to TraI 284-821 with a macroscopic association constant (KN) of 9.8×10
6
 M
-1
.   
To examine if TraI 284-821 can bind unlabeled nucleotides, a competitive binding 
assay was performed using TNP-ATP as a reference. In this assay, TraI 284-821 was titrated 
with TNP-ATP in the presence of 800 μM unlabeled ATP or ADP (Figure 1.1). If unlabeled 
nucleotides can compete with TNP-ATP for the nucleotide binding site, the titration curve 
will shift to a higher TNP-ATP concentration in the presence of unlabeled nucleotides. 
Indeed, our results show that the presence of unlabeled ATP or ADP shifted the titration 
curve to the right, or the higher TNP-ATP concentration. More prominent shift was observed 
in the presence of ATP. These results suggest that unlabeled ATP and ADP can bind to TraI 
284-821. Moreover, TraI 284-821 has a stronger affinity for ATP than ADP. 
We examined the stoichiometry of nucleotide binding to full-length TraI by titrating 
TraI at two different concentrations (0.5 and 3 μM) with TNP-ATP as described in the 
material and methods (Figure 1.2A). The degree of binding was calculated as described by 
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Bujalowiski et al.(34). The binding stoichiometry of TraI with TNP-ATP was determined by 
examining the dependence of normalized fluorescence intensity on the binding density from 
the titration curves (Figure 1.2B). The binding stoichiometry of TraI with TNP-ATP was 
estimated to be two TNP-ATP molecules per TraI molecule, since the degree of binding 
equaled two at the maximum normalized fluorescence intensity Given that it is known that 
the established helicase domain TraI 822-1476 contains one nucleotide binding site, our 
result suggests the presence of a second nucleotide binding site outside TraI 822-1476. 
Considering that TraI 1-300 (the relaxase domain) and TraI 1476-1756 (the protein 
interaction domain) do not bind nucleotides, our results support the notion that TraI 284-821 
contains a nucleotide binding site.  
 
The NTPase activity of TraI 284-821 
We examined the ATPase and GTPase activities of TraI 284-821 using the NADH-
coupled NTPase assay as described in the materials and methods. The ATPase activity of 
full-length TraI was measured here as a reference. The results are summarized in Table 1.2. 
Under our assay conditions TraI 284-821 only displayed residual ATPase activity, and had 
no observable GTPase activity (Figure 1.3A). The catalytic efficiency of TraI 284-821 is 
only 0.006% of that of full-length TraI (Table 1.2). The ATPase activity of TraI 284-821 
dropped for about 95% in the absence of ssDNA (Figure 1.3B), indicating that the ATPase 
activity of TraI 284-821 is ssDNA-dependent.  
To understand why TraI 284-821 only retains residual ATPase activity, we examined 
the primary sequence of TraI 284-821. Sequence alignment of different TraI orthologs 
reveals that TraI 284-821 loses the consensus Walker A motif (GxxxGKT/S) of the RecD 
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helicase that is crucial for catalysis of NTP hydrolysis (Figure 1.4). The key catalytic lysine 
residue of the Walker A motif could be replaced by the arginine-446 in TraI 284-821. 
However, our results show that TraI 284-821 R446M displayed wide-type level ATPase 
activity, suggesting that arginine-446 is not the catalytic residue of TraI 284-821. Our results 
suggest that TraI 284-821 only retains residual ATPase activity likely due to the loss of 
critical catalytic motifs. 
 
Binding of TraI helicase to ssDNA: determination of the site-size and DNA binding 
parameters.  
The interaction between protein and DNA can be studied conveniently by quantitative 
titrations of a fluorescently labeled DNA with the protein of interest. However, the binding 
parameters obtained in this manner are often inaccurate due to the interference from the 
fluorescent probe. To understand the intrinsic DNA-binding property of TraI, we have 
studied the interaction of TraI with unlabeled DNA oligomers using the Macromolecule 
Competition Titration (MCT) method as described by Bujalowski et al. (31) (see also 
materials and methods). This method has been successfully applied to the analysis of the 
interactions of the PriA and RepA helicases with DNA (35, 36).  In brief, a fluorescently 
labeled DNA oligomer, or the reference DNA, is titrated with TraI in the absence or presence 
of an unlabeled DNA oligomer, or the competing DNA, whose binding parameters are to be 
determined. Because the association of the unlabeled ssDNA oligomer with TraI does not 
give significant anisotropy signal, the presence of the unlabeled DNA oligomer will shift the 
titration curve to higher TraI concentration as compared to the curve generated in the absence 
of competitor. Based on the shift of the titration curve, this method allows the determination 
of the binding stoichiometry of TraI with an unlabeled DNA oligomer. The MCT method 
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also enables the construction of a model-independent binding isotherm, which can be used 
for the determination of thermodynamically rigorous binding parameters for the unlabeled 
DNA oligomer. All protein constructs and DNA oligomers used for this study are listed in 
Figure 1.9 and Table 1.1.   
The interaction of TraI with a series of unlabeled ssDNA oligomers of different 
lengths was studied using the MCT method (31). Titration of 50 nM FL-T17 (fluorescently-
labeled T17) with TraI in the absence or presence of 200 nM or 350 nM ssDNA oligomers of 
lengths ranging from 13 to 63 nucleotides were conducted in standard DNA binding buffer 
(Figure 1.7A and 1.7B). The unlabeled 13-, 15- and 17-mer ssDNA did not cause significant 
shift of the titration curves to higher TraI concentration, suggesting that TraI cannot bind 
tightly to unlabeled 13-, 15- and 17-mer under our assay conditions.  
The binding stoichiometry of TraI with the 39-mer was determined by examining the 
dependence of anisotropy values on the binding density from the titration curves (Figure 
1.7C). The binding stoichiometry of TraI with the 39-mer was estimated to be one, since  
binding density equaled one at the maximum anisotropy value of 291. Analogous analyses of 
the binding stoichiometry were performed for DNA oligomers varying in length from 17 
nucleotides to 63 nucleotides. The dependence of maximum stoichiometry on the length of 
ssDNA oligomers indicated that 51- and 63-mers can accommodate two TraI molecules, 
while ssDNA oligomers shorter than 45 nucleotides can only accommodate one TraI 
molecule (data not shown).  
To determine the binding parameters of TraI for the ssDNA oligomers, we 
constructed model-independent binding isotherms for each ssDNA oligomers. Since ssDNA 
13-, 15-and 17-mer did not create a significant shift in the titration curve, their binding 
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isotherms could not be accurately determined. The binding isotherms for the 19-mer and 
longer oligomers are shown in Figure 1.8A and 1.8B. The macroscopic binding constants 
(KN) for 31-mer and below were determined by analyzing the binding isotherms with 
equation 11 since these DNA oligomers can only accept one TraI molecule; the results are 
summarized in Table 1.4. The dependence of KN on the length of ssDNA oligomers (N) can 
be clearly divided into two phases. KN increased relatively slowly when N < 25, but faster 
when N >25. A roughly linear relationship between KN and N was observed when N ranges 
from 25 to 31 nucleotides (Figure 1.8C). An explanation for this linear relationship is that 
TraI experiences multiple potential binding sites on a ssDNA longer than 25 nucleotides, 
indicating that the ssDNA binding site size of TraI is about 25 nucleotides (32, 37, 38). The 
observed dramatic increase in KN was caused by a statistical factor arising from the existence 
of multiple potential binding sites, instead of the formation of more contacts between TraI 
and ssDNA oligomers. This statistical factor can be defined in terms of the intrinsic binding 
constant (Kint) and the total site-size (m) as (35, 36):  
int( 1)NK N m K                   
(13) 
This empirical linear relationship usually appears only when the length of the DNA 
oligomer is longer than the total site-size. In contrast, the slow increase of KN with N when 
N<25 likely reflects the formation of increasing contacts between TraI and DNA. The 
intrinsic binding constants (Kint) for the ssDNA that bind one TraI molecule were determined 
by analyzing the binding isotherms in Figure 1.8A using equation 10 under the condition 
m=25. The results were summarized in Table 1.4. The Kint did not change significantly with 
the length of the ssDNA oligomers, ranging from 1.8 ± 0.5 to 2.6 ± 0.3 ×10
7
 M
-1
. This result 
supports the estimation of the total site-size to be 25 nucleotides.  
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Since the total site-size is approximately 25 nucleotides, complete engagement of the 
ssDNA binding site of two TraI molecules should require ssDNA of at least 50 nucleotides. 
To determine the cooperativity parameter (ω) for TraI binding to ssDNA, we analyzed the 
interaction of TraI with the ssDNA 63-mer. The corresponding binding isotherm, shown in 
Figure 1.8B, was analyzed using the Epstein Equation under the condition m=25 and g=2. 
The Kint and ω were determined to be 6.7 (± 0.2) ×10
5 
M
-1
 and 33.4 (±) 2.4, respectively. Our 
data clearly indicate that TraI binds to ssDNA oligomers with low cooperativity.  
Binding of TraI to dsDNA: determination of the site-size and binding parameters.  
We next examined the interaction of TraI with unlabeled dsDNA using the MCT 
method (31). Titration of 100 nM FL-dsDNA15 with TraI in the absence or presence of 500 
nM unlabeled dsDNA oligomers of length ranging from 9 to 27 base pairs in buffer A was 
performed (Figure 1.9A). Oligomers shorter than 9 base pairs were not studied here because 
they have low melting temperatures and are unstable at the temperature of the experiment (25 
o
C). The binding stoichiometry of TraI with dsDNA oligomers was estimated from the plot 
of fluorescence anisotropy versus binding density (Figure 1.9B), as described above. The 
dependence of binding stoichiometry on the length of dsDNA oligomers indicated that the 
19-, 23- and 27-mer dsDNA can accept two TraI molecules, while 11- and 15-mer dsDNA 
can only bind one TraI molecule (Table 1.5). The fact that a 19-mer, but not a 15-mer 
dsDNA, can accommodate two TraI molecules indicates that each TraI molecule 
encompasses at least 8~9 base pairs when forming a stable complex with a dsDNA.   
Next, the intrinsic binding constant (Kint) was determined by fitting the binding 
isotherms (Figure 1.9C) with the Epstein Equation under the conditions that the site-size m=9 
and the maximum binding density g=1 (for 9-, 11- and 15-mer) or g=2 (for 19-, 23- and 27-
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mer). These results are summarized in Table 1.5. The large error in Kint for the 9-mer resulted 
from the low binding density of TraI on the 9-mer under our assay conditions (Figure 1.9C). 
Our data show that TraI has a similar Kint for dsDNA of lengths ranging from 11 to 27 base 
pairs, supporting the hypothesis that TraI contacts approximately 9 bps when it forms a 
complex with dsDNA. TraI does not bind dsDNA oligomers in a highly cooperative fashion, 
as evidenced by ω values ranging from 14.8 ± 2.2 to 38.6 ± 7.7 for dsDNA ranging in length 
from 19 to 27 base pairs. 
 
Identification of the dsDNA binding site. 
To identify the dsDNA binding site, we designed a series of TraI constructs based on 
the proposed domain organization of TraI (Figure 1.6) and examined their interaction with 
FL-dsDNA15 using the direct DNA binding assay (30) (Figure 1.10A). Macroscopic binding 
constants, KN, were determined by fitting the titration curves using a one-site binding model 
(equation 3) and are summarized in Table 1.5. The affinity of TraI 1-1476 and TraI 1-858 for 
FL-dsDNA15 were comparable to that of full-length TraI, suggesting that the dsDNA binding 
site is located N-terminal to residue 858. TraI 1-330, a construct that contains the relaxase 
domain, cannot bind FL-dsDNA15 under our assay condition (Figure 1.10A). However, the 
deletion of 1-301 dramatically reduced the affinity of TraI for FL-dsDNA15. The binding 
affinity of TraI 302-1756 for FL-dsDNA15 is about 20-fold lower than that of full-length TraI. 
These results indicate that while the dsDNA binding site is primarily located between 
residues 302-858, the relaxase domain facilitates the binding of dsDNA.  
A helicase-associated ssDNA binding site is located at the N-terminal region of TraI 
(302-820) (14). Therefore, it is possible that the dsDNA binding site identified here overlaps 
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with the ssDNA binding site. To test this possibility, we performed a competition binding 
assay using FL-dsDNA15 as the reference DNA and the ssDNA oligomer T25 as the 
competitor DNA. Under our experimental conditions, a complex of TraI with FL-dsDNA15, 
but not with T25, can generate a fluorescence anisotropy signal. If T25 effectively competes 
with FL-dsDNA15 for the dsDNA binding site of TraI, the total anisotropy value will drop 
with an increase in the concentration of T25. Indeed, the total anisotropy value decreased with 
the increase of T25 concentration with an apparent IC50 of 1.5 μM (Figure 1.10B). This 
suggests that the binding of T25 and FL-dsDNA15 by TraI occurs along an overlapping, if not 
identical binding surface. 
 
Modulation of DNA binding affinity by nucleotides.  
We evaluated the effect of nucleotides on the affinity of TraI for unlabeled ssDNA 
oligomers using the MCT method (31).  Titration of 50 nM FL-T17 with TraI in the absence 
or presence of T25 and in the absence or presence of ADP or the nonhydrolyzable ATP 
analogue, AMPPNP, was performed in buffer B (Figures 1.14A, 1.14B, 1.14C), and a model-
independent binding isotherm was constructed (Figure 1.11D). The Kint for T25 in the absence 
of any nucleotides was determined to be 2.8 (± 0.4) × 10
7
 M
-1
 by analyzing the binding 
isotherm using equation 10 under the condition m=25. Since TraI can slowly hydrolyze ATP 
in the presence of T25 under our assay conditions, the nonhydrolyzable ATP analogue 
(AMPNP) was used instead of ATP. The presence of 1 mM ADP and AMPPNP increased 
the Kint of TraI for T25 to 1.2 (± 0.3) × 10
8
 and 1.4 (± 0.4) × 10
8
 M
-1
, respectively. These 
results demonstrate that the binding of ADP and AMPPNP slightly enhance the affinity of 
TraI for ssDNA. 
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Effect of ionic strength on DNA binding.  
To further define the DNA binding properties of TraI, we examined the effect of ionic 
strength on the affinity of TraI for ssDNA and dsDNA using the direct DNA binding assay 
(30). Titration of 50 nM FL-T25 was performed in buffer C supplemented with increasing 
concentrations of NaCl: 50, 75, 100 and 125 mM.  To avoid the interference of Mg
2+
, buffer 
C did not contain magnesium acetate and was supplemented with 1 mM EDTA. Analogous 
experiments were performed for FL-dsDNA15.  The affinity of TraI for ssDNA and dsDNA 
decreased with the increase of NaCl concentration (Figure 1.12A). The Kint for FL-T25 is 1.1 
(± 0.3) × 10
8
 M
-1
 when [NaCl]=50 mM. A 3.4-fold decrease in Kint was observed when 
[NaCl] was increased to 125 mM NaCl. More dramatic change in Kint was observed with FL-
dsDNA15, with Kint decreasing about 36-fold when [NaCl] increased from 50 to 125 mM 
(Figure 1.12A). Within experimental error, a linear relationship between ln(Kint) and 
ln[NaCl] was detected for both FL-T25 and FL-dsDNA15, with slopes of -1.2 ± 0.2 and -3.7 ± 
0.2, respectively, suggesting that the binding of TraI to FL-T25 and FL-dsDNA15 was 
accompanied with the net release of about one and four ions respectively. These results 
suggest that electrostatic interactions are crucial for the stability of TraI-DNA complex. 
Moreover, electrostatic interactions play a more important role in the interaction of TraI with 
dsDNA. 
 
Base specificity of DNA binding.   
Base specificity in interactions of TraI with unlabeled ssDNA oligomers was 
addressed using the MCT method (31). Titration of 50 nM FL-T17 with TraI in the absence or 
presence of 250 nM unlabeled 25-mer ssDNA (Figure 1.12B). This 25-mer ssDNA contains 
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a mixture of four types of bases and does not form any secondary structure or duplex under 
our assay conditions. The presence of the 25-mer ssDNA shifted the titration to higher 
protein concentration, suggesting competition between the 25-mer ssDNA and FL-T17 
(Figure 1.12B). A model-independent binding isotherm for the 25-mer ssDNA and 
subsequent analysis using equation 9 under the condition m=25 gave an intrinsic binding 
constant, Kint = 8.7 (± 0.3) ×10
6
 M
-1
 (Figure 1.12C). Analogous titrations of FL-T17 in the 
presence of T25 or C25 indicate a pronounced shift in titration curves (Figure 1.12B). These 
data indicate that C25 and T25 compete more efficiently with FL-T17 for TraI than does the 25-
mer ssDNA.  Binding of TraI to T25 and C25 were characterized by a Kint = 2.5 (± 0.2) ×10
7
 
and 5.8 (± 0.1) ×10
7 
M
-1
, respectively. These data indicate that TraI prefers to bind ssDNA 
oligomers containing a single type of base, with a further preference for pyrimidine 
oligomers. G25 was not examined here because it tends to form a cruciform structure and is 
not easily synthesized. The presence of A25 dramatically interfered with the fluorescence 
anisotropy signal, making the titration curves in the absence or presence of A25 
incomparable. As a result, the binding constant for A25 was not determined by the MCT 
method. 
 
Spatial organization of the TraI domains.  
Although the crystal structures of several domains of TraI are available, there is no 
known structure of a full-length TraI. To elucidate the spatial organization of the TraI 
domains, we examined full-length TraI by SAXS, which allows the construction of a low-
resolution structural envelope for a macromolecule. Many important structural parameters, 
such as the radius of gyration (Rg) and the maximum dimension (Dmax), can also be obtained 
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by analyzing the SAXS profile. The SAXS experiments were performed on TraI solutions 
over a concentration range of 0.5-2 mg/ml. The SAXS profile and the linearity of the Guinier 
region indicated that TraI was well behaved and free of aggregation (Figure 1.13A). The Rg 
for TraI as obtained by the Guinier approximation was 58.5 ± 0.9 Å (Figure 1.13A inset). 
The Dmax of TraI was 220 Å as determined from the P(r) function, calculated using the 
program GNOM (Figure 1.13B). The P(r) function reflects the probable distribution of inter-
atomic distances within the scattering particles. The asymmetric feature of the P(r) function 
suggested that TraI exists in an elongated shape in solution.  
To better define the geometric shape of TraI, we performed ab inito shape restoration 
of TraI using the program DAMMIN (24). Forty independent runs were performed and initial 
parameters were intentionally varied between runs. Independent runs generated very similar 
structural envelopes, signifying consistency between different runs and reliability of the 
generated structural envelopes. The forty structural envelopes were ranked based on their 
respective χ2.  The top twenty envelopes (χ2 ≈ 0.34) were averaged to generate the final 
SAXS envelope that is approximately 220 Å × 82 Å × 65 Å (Figure 1.13C). The envelope 
features a highly extended structure with two protuberances at each end of the longest 
dimension.  This structural envelope was used as a guide for the determination of the spatial 
organization of TraI domains in the following analysis.  
In combination with atomic models, the structural envelope generated from SAXS 
data can be used to determine the domain organization of a multi-domain protein. While 
crystal structures are available for the relaxase domain (1-236, 267-307) and part of the C-
terminal domain (1476-1628), atomic structures are missing for the rest of the protein. We 
used the program PHYRE (27) to generate homology models for these two regions. The 
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homology models of TraI 309-842 and 846-1473 were successful generated by PHYRE using 
the crystal structure of E.coli RecD (PDB entry, 1W36) as a template. Due to the lack of 
homology, 56 and 74 residues are missing from the final models of TraI 309-842 and 846-
1473 respectively. Also, PHYRE failed to generate a model for TraI 1629-1756 due to the 
lack of a homologous template. As a result, the region encompassing residues 1629-1756 was 
not incorporated into the following analysis.  
A rigid-body model of TraI was generated by manual placement of TraI domains into 
the SAXS envelope. The flat and extended shape of the TraI envelope, and the constraints of 
inter-domain connectivity, allowed relatively little ambiguity in determining the position of 
the four structural domains of TraI. The crystal structure of the relaxase domain was 
manually placed into the protuberance at one end of the envelope initially. Then, homology 
models of the two RecD-like domains were placed into the main body of the envelope, which 
was the only portion of the envelope that could accommodate the combined size of these two 
domains. Numerous positions and orientations of these two RecD-like domains were 
examined to minimize the discrepancy (χ2) between the calculated scattering intensities and 
the experimental scattering intensities. The connectivity of contiguous domains was used as a 
constraint for placement. Finally, the crystal structure of the C-terminal domain was modeled 
into the protuberance at the other end of the envelope. Part of the envelope at the C-terminal 
end is empty due to the missing of residues 1629-1756. The rigid-body model of TraI 
generated here has acceptable geometry and gave a satisfactory χ2 of 5.0 (Figure 1.13A), 
especially considering that 292 of 1756 residues are missing from the atomic models. In this 
model, the four domains of TraI aligned along a single axis, with the relaxase domain and the 
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C-terminal domain at the opposite ends, and the two RecD-like domains juxtaposed in the 
middle (Figure 1.13D).  
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1.4 Discussion 
TraI has a long ssDNA binding site.  
Most helicases require the presence of a single-stranded tail for the unwinding of 
duplex DNA. Typical superfamily I helicases, such as UvrD and RecD, can efficiently 
unwind a duplex DNA with a single-stranded tail of 10~12 nucleotides (39, 40). However, 
TraI requires at least a 27-nucleotides tail for efficient unwinding and cannot unwind duplex 
DNA if the tail is shorter than 20 nucleotides (41). Quantitative analysis in this work suggests 
that the unusually long single-stranded tail required by TraI for DNA unwinding arises from 
its unique ssDNA binding property. TraI only weakly binds ssDNA oligomers shorter than 
19 nucleotides, potentially explaining why TraI cannot unwind duplex DNA when its single-
stranded tail is shorter than 20 nucleotides. Considering that the ssDNA binding site of TraI 
can encompass up to 25 nucleotides, and that, for optimal helicase activity, the minimal 
single stranded  overhang requirement is 27 nucleotides, it appears that full engagement of 
the ssDNA binding site by DNA may trigger efficient  DNA unwinding by TraI.  
 
TraI binds to ssDNA with low cooperativity.  
TraI displayed low cooperativity (ω= 33.4 ± 2.4) when binding to a ssDNA oligomer 
that can accept two TraI molecules, indicating that no significant cooperative interactions 
existed between the two bound TraI molecules. High cooperativity (ω values between 102 to 
10
5
) is often associated with multimeric DNA binding proteins and proteins whose main 
function is to cover DNA (42, 43). Previous studies show that TraI functions as a processive 
helicase as a monomer in vitro (17). The low DNA binding cooperativity observed here 
supports the monomeric nature of TraI. Low cooperativity during DNA binding is also 
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associated with many other helicases and DNA binding proteins that function as a monomer, 
including helicase RecQ (44) and ssDNA binding protein ICP8 (45). It is interesting to note 
that the low cooperativity during DNA binding might also reflect a physiological adaptation 
of TraI to function as a single protein in the context of the relaxosome. Many DNA helicases, 
which function as a part of a large machinery, such as PriA and DnaB, have been reported to 
display low cooperativity during DNA binding (34, 46, 47).  
 
The dsDNA binding site might play a role in the assembly of the relaxosome.  
It is of interest to find that TraI can bind dsDNA in the absence of any other protein in 
vitro. The intrinsic binding constant for dsDNA was determined to be about 5×10
5
 M
-1
 
(Table 1.5), which is significantly lower than that for ssDNA (Table 1.4). The low affinity of 
TraI for dsDNA might explain why TraI-dsDNA binding was not detected in the study by 
Matson et al., in which the highest TraI concentration examined was 100 nM (48). Our 
deletion studies show that the dsDNA binding site is located at the N-terminal region (1-858) 
of TraI and likely overlaps with the helicase-associated ssDNA binding site. Given that the 
affinity of TraI for dsDNA is at least one magnitude lower than its affinity for ssDNA, 
dsDNA binding will likely be outcompeted by ssDNA binding when ssDNA, long enough to 
form stable complex with TraI, is available. Therefore, we consider that this dsDNA binding 
site will not be engaged during the unwinding of duplex DNA when a long stretch of ssDNA 
is available. However, this dsDNA binding site might play a role in the assembly of the 
relaxosome when ssDNA is not available. Biochemical studies indicate that TraI alone can 
bind to a supercoiled dsDNA that contains the oriT site in vitro (49). The interaction, 
however, is sensitive to NaCl concentration and completely inhibited when the NaCl 
 28 
 
concentration is above 75 mM (48). The binding of TraI to supercoiled dsDNA might be 
mediated by the dsDNA binding site identified here. Our observation that the affinity of TraI 
to dsDNA is very sensitive to NaCl concentration explains the sensitivity of relaxosome 
formation to NaCl concentration.  
 
Spatial organization of TraI domains. 
 TraI is a bifunctional protein which contains four major structural domains. 
Understanding the spatial organization of these domains will provide insight into the relative 
contribution of each domain to TraI function. The SAXS-generated model of TraI reveals 
that the protein assumes an extended shape in solution with the four structural domains 
aligning along one axis. The relaxase domain is located at one end of the model and creates a 
limited number of contacts with the remainder of the protein (Figure 1.13D). This domain 
configuration provides the relaxase domain significant flexibility that is likely essential for 
the function of TraI. The two RecD-like helicase domains are modeled into the middle of the 
SAXS envelope and together form multiple intimate contacts, suggesting they may function 
as a unit. The CTD is at the opposite end of the model relative to the relaxase domain, 
consistent with the independent activities of these two domains. The extended conformation 
of TraI allows for the formation of contacts between each sequential domain of TraI, as well 
as between TraI and other proteins.  This network of contacts may play a role in the 
regulation of the relaxase and helicase activities of TraI.   
A model of the TraI helicase in complex with a DNA substrate containing a dsDNA-
ssDNA junction was assembled based on the SAXS envelope (Figure 1.14). In this model, 
the location of the dsDNA-ssDNA junction was determined based upon the location of the 
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―pin‖ domain, or subdomain 1B, of RecD-like domain II, which has been proposed to contact 
duplex DNA in structural studies of RecD proteins (50). The 5’ ssDNA overhang binds to the 
long ssDNA binding groove formed by the two RecD-like domains. Two possible end 
structures of the 5’ ssDNA overhang are presented here. Based on the common belief that 
one TraI molecule carries out both nicking at oriT and ensuing duplex DNA unwinding, the 
5’ end of the ssDNA will be covalently attached to the relaxase domain. Recall that the 
catalytic tyrosine residue of the relaxes domain forms covalent linkage with the 5’ end of 
ssDNA upon nicking at oriT. Recent discoveries from Schildbach et al. that nicking at oriT 
and ensuing duplex DNA unwinding could be performed by two different TraI molecules 
(51) suggests that the 5’ end of the ssDNA could also stay unattached during the unwinding. 
The 3’ ssDNA overhang is not bound by the protein in this model, due to the fact that the 
presence of a 3’ ssDNA overhang does not enhance the affinity of TraI for DNA 
(unpublished data).   
 
The contribution of RecD-like domain I to the processivity of TraI helicase.  
TraI functions as a highly processive monomeric helicase (17). The helicase domain 
of TraI contains two RecD-like domains, one with intact helicase motifs (domain II) and one 
in which the helicase motifs are not present (domain I) (14) (Figure 1.6). The N-terminal 
RecD-like domain I retains ssDNA binding capacity (14). Our SAXS model suggests that the 
two RecD-like dains are closely associated with one another and may form a continuous 
ssDNA binding groove. Similar domain organization has been observed in the structure of 
the multimeric E.coli helicase RecBCD (52). Alone, RecB is a monomeric 3’-5’ helicase 
with limited processivity. Similar to the RecD-like domain I of TraI, RecC has a helicase-like 
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fold but lacks both helicase activity and key helicase motifs. Together, RecBC, a heterodimer 
formed by RecB and RecC, has significantly higher processivity than RecD alone (52, 53). 
The crystal structure of the complex clearly shows that the DNA binding sites of RecB and 
RecC are brought together in the heterodimer, forming a long and continuous ssDNA binding 
groove (52). The extended binding groove likely facilitates the association of RecB with 
ssDNA during translocation. We propose that in TraI, RecD-like domain I functions as a 
processivity domain to assist the motor domain, RecD-like domain II, in a manner analogous 
to the RecBC complex. 
 
AMPPNP and ADP enhance the affinity of TraI for ssDNA.  
Helicases utilize the energy from NTP hydrolysis to unwind nucleic acids. During 
each cycle of the NTPase reaction, helicases process through a number of distinct nucleotide 
binding states including unbound, NTP-bound and NDP-bound. In current models, the 
transitions between nucleotide binding states during the NTPase reaction result in 
conformational changes in the nucleic acid binding site of the helicase, thereby driving the 
translocation of the helicase along the nucleic acid (54). To understand how the 
conformational states of TraI are controlled by its nucleotide binding states, we examined the 
effects of nucleotide concentration on the affinity of TraI for ssDNA. Our data illustrate that 
the presence of AMPPNP or ADP results in an approximate 3-fold increase in ssDNA 
binding affinity by TraI. This indicates that TraI exists in two distinct conformational states 
during each cycle of the NTPase reaction. When the nucleotide binding site is empty, TraI 
stays in a conformational state that has relatively low affinity for ssDNA (the loose state). 
The binding of ATP switches TraI into a conformational state that binds ssDNA with higher 
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affinity (the tight state). At the end of the cycle, TraI returns to the loose state following the 
release of ADP. The presence of two different conformational states during each NTPase 
cycle has been observed in most established helicases, while the detailed mechanism can 
vary. For example, the Rep helicase stays in a tight DNA binding state in the absence of any 
nucleotide. It switches into a loose DNA binding state upon the binding of ATP. Upon the 
hydrolysis of ATP, the Rep helicase returns back to the tight state (55).  
In summary, we have integrated biochemical and structural data to provide the first 
comprehensive model of the interaction of the TraI helicase with DNA. This model provides 
insight into the mechanism of the TraI helicase, and in particular suggests how the TraI 
helicase can achieve such an exceptional processivity through the cooperation of the two 
RecD-like domains. 
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1.5 Figure Legends 
Figure 1.1  Binding of nucleotides to TraI 284-821. Titration of full-length TraI with TNP-
ATP was preformed at 22 ºC in the absence or presence of 800 μM unlabeled ATP or ADP 
as described in the materials and methods. The binding buffer contained 20 mM Tris-HCl 
(pH 7.5) and 20 mM NaCl. The solid lines are used to separate the data and do not have any 
theoretical basis.  
 
Figure 1.2  The stoichiometry of TraI binding to TNP-ATP. A) Full-length TraI was 
titrated with TNP-ATP at two different concentrations at 22 ºC as described in the materials 
and methods. The binding buffer contained 20 mM Tris-HCl (pH 7.5) and 20 mM NaCl. B) 
Dependence of the normalized fluorescence increase on the degree of binding. The sold line 
represents a linear computer fit of the data. The maximum relative fluorescence increase is 
indicated by a dashed horizontal line. The binding stoichiometry was estimated to be two 
ATP molecules per full-length TraI molecule.  
 
Figure 1.3  The ATPase and GTPase activities of TraI 284-821. A) The ATPase and 
GTPase activities of TraI were measured at 37 ºC by the NADH-coupled NTPase assay as 
described in the materials and methods. The reaction mixture (75 μl) contained 50 mM Tris-
HCl (pH 7.5), 10 mM  MgAcO, 600 μM NADH, 25 mM NaCl, 25 mM K2SO4, 0.1% BSA, 
700 μM Phosphoenolpyruvate (PEP), 3 unit PK and 3.6 unit LDH, 40 nM ssDNA 
M13MP18, 1 μM TraI 284-821 and indicated concentrations of ATP/GTP. The kinetic 
parameters were calculated by fitting the data with the Michaelis-Menten equation and 
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summarized in Table 1.2 and 1.3 B) The ATPase activity of TraI 284-821 in the presence or 
absence of 40 nM ssDNA M13MP18.     
 
Figure 1.4  Sequence alignment of TraI orthologs. A) Sequence alignment of different 
TraI orthologs. Only the sequence around the putative Walker A motif (Motif I) and Walker 
B motif (Motif II) of TraI 284-821 are shown. The critical residues are higlighgted with stars. 
B) Comparison of the Motif I and Motif II of TraI 284-821 with the classical Walker A and 
Walker B motifs. x and h respresent any amino acid and hydrophobic amino acids 
respectively. The catalytic lysine residue of the classical Walker A motif and the putative 
catalytic arginine residue (R446) of the motif I are shown in bold and italics. 
 
Figure 1.5   The role of R446 in the ATPase activity of TraI. The ATPase activities of 
wide-type TraI 284-821 and TraI 284-821 R446M were measured at 37 ºC by the NADH-
coupled NTPase assays as described in the materials and methods.  
 
Figure 1.6   Schematic representations of the domain organization of TraI and the TraI 
constructs used in this study. The N-terminal relaxase domain contains residues 1-309; 
helicase domain, 310-1476 and the C-terminal domain (CTD), 1477-1504. The asterisk 
indicates the location of the catalytic residue K998. RecD-like domain I (303-844) and 
RecD-like domain II (830-1473) identified by sequence analysis (14) are highlighted in dark 
lines. TraI constructs are shown in open boxes, whose first and last residues are indicated.  
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Figure 1.7  Determination of the stoichiometry of ssDNA binding by TraI. Titration of 50 
nM FL-T17 with TraI was performed in the presence or absence of 200 nM Tn (n ranges from 
13 to 31) (A) and 350 nM 39-mer, 45-mer, 51-mer and 63-mer ssDNA (B) in standard DNA 
binding buffer at 25 
o
C. The solid lines are used to separate the data and do not have any 
theoretical basis. C) Dependence of observed anisotropy on the total averaged binding 
density of TraI on the 39-mer. This plot was constructed based on the titration curve in (B) 
using the MCT analysis (31). The short solid line indicates the maximum value of the 
observed anisotropy. The stoichiometry was estimated to one TraI molecule per 39-mer from 
this plot.  
 
Figure 1.8  Determination of binding parameters for TraI binding to ssDNA. A) Model-
independent binding isotherms of TraI to unlabeled ssDNA Tn (n ranges from 19 to 31). The 
binding density and the corresponding concentration of free TraI were calculated from the 
titration curve in Figure 2A using the MCT analysis (31). The solid lines are computer fits of 
the data using equation 10 under the condition m=25 or equation 11. The macroscopic 
binding constants (KN) and intrinsic binding constants (Kint) derived from curve-fitting are 
summarized in Table 1.4. B, Model-independent binding isotherm of TraI to 63-mer ssDNA. 
The solid line is computer fit of the data using the Epstein combinatorial approach (equation 
8 & 9) under the condition m=25 and g=2. The best fit gives Kint = 6.7( ± 0.2) ×10
5
 M
-1
 and ω 
= 33.4 ± 2.4. C, Dependence of KN on the length of the ssDNA oligomers. The solid line is 
the linear fit of the data points for T25, T27, T29 and T31.  
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Figure 1.9  Determination of stoichiometry and binding parameters for TraI binding to 
dsDNA. A, Titration of 100 nM FL-dsDNA15 with TraI was performed in the absence or 
presence of 500 nM dsDNA of different lengths (ranging from 9 to 27 residues) in buffer A 
at 25 
o
C. The solid lines are used to separate the data and do not have any theoretical basis. B, 
Dependence of observed fluorescence anisotropy on the total averaged binding density of 
TraI on the 15-mer dsDNA. The short solid line indicates the maximum value of the 
observed anisotropy. C, Model-independent binding isotherms of TraI to unlabeled dsDNA 
of different lengths, ranging from 9 to 27 base pairs. The binding density and the 
concentration of free TraI were calculated from the titration curves in (A) using the MCT 
analysis (31). The solid lines are computer fits of the data using the Epstein combinatorial 
approach (equation 8 & 9). The parameters were m=9 and g=1 for dsDNA9, dsDNA11 and 
dsDNA15 and m=9, g=2 for dsDNA19, dsDNA23 and dsDNA27. The intrinsic binding 
constants (Kint) and cooperativity parameters (ω) derived from computer fits are summarized 
in Table 1.5. 
 
Figure 1.10  Identification of the location of the dsDNA binding site. A, Titrations of 50 
nM FL-dsDNA15 with different TraI deletion mutants were performed using the direct DNA 
binding assay in standard DNA binding buffer at 25 
o
C. The solid lines are computer fits of 
the binding curves using a one-site binding model (equation 3). The macroscopic binding 
constants, KN, derived from the computer fits are summarized in Table 1.6. B, Competition of 
dsDNA and ssDNA for the binding of TraI. Titration of a mixture of 100 nM FL-dsDNA15 
and 100 nM TraI with increasing concentration of 25-mer ssDNA, T25, was performed in 
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buffer A at 25 
o
C.  The solid line is the computer fit of the curve using non-linear least square 
regression. 
Figure 1.11  ADP and AMPPNP increased TraI affinity for ssDNA. Titration of 50 nM 
FL-T17 with TraI was performed in the absence or presence of 350 nM T25 in buffer B (A)), 
supplemented with 1 mM AMPPNP (B) or 1 mM ADP (C) at 25 
o
C. The solid lines are used 
to separate the data and do not have theoretical basis. (d) Model-independent binding 
isotherms of TraI to T25 in the absence or presence of 1 mM ADP or AMMPNP. The binding 
density and the concentration of free TraI were calculated from the titration curves in (A)), 
(B), and (C) using the MCT analysis (31). The solid lines are computer fits of the data using 
the Epstein combinatorial approach (equation 10) under the condition m=25. The intrinsic 
binding constants (Kint) for T25 in the absence of any nucleotide or in the presence of 1mM 
ADP or AMPPNP are 2.8 (± 0.4) ×10
7
, 1.4 (± 0.4) ×10
8
, and 1.2 (± 0.3) ×10
8 
M
-1
, 
respectively. 
 
Figure 1.12  The role of ionic strength and base specificity in TraI DNA binding. A), 
Dependence of binding affinity on NaCl concentration. 50 nM FL-T25 or FL-dsDNA15 were 
titrated with TraI in buffer C supplemented with different concentrations of NaCl: 50, 75, 
100 and 125 mM. The titration curves are not shown here. The intrinsic binding constants, 
Kint, at different NaCl concentrations were determined by fitting the titration curves using the 
Epstein combinatorial approach (equation 10). The data presented here are averages from 
three independent experiments. The solid lines are linear least-square fit of the data. The 
slopes of the computer fits for FL-T25 and FL-dsDNA15 are -1.2 ± 0.2 and -3.7 ± 0.2 
respectively. B. Binding of TraI to ssDNA with different base compositions. Titration of 50 
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nM FL-T17 with TraI was performed in the presence or absence of 250 nM N25, T25 and C25, 
in standard DNA binding buffer at 25 
o
C. The solid lines are used to separate the data and do 
not have any theoretical basis. C, Dependence of binding density on the concentration of free 
TraI. The binding density and the concentration of free TraI were calculated from the binding 
curve in (B) using the MCT analysis (31). The solid lines are computer fits of the data using 
the equation 10. The Kint for N25, T25, and C25, are 5.4 (± 1.1) ×10
6
, (2.5 ± 0.2) ×10
7
, and 5.8 
(± 0.1) ×10
7 
M
-1
, respectively.  
 
Figure 1.13   Solution structure of TraI. A), SAXS profiles of TraI. The theoretical 
scattering profile of the rigid-body model for TraI (figure 8D) is shown by the red dashed 
line. The inset is the Guinier plot of the experimental scattering profile. The solid lines are 
least-square linear fits of the data under the condition Rg × q ˂ 1.3. B, P(r) plot of TraI. The 
maximum dimension (Dmax) is derived to be 220 Å. C, DAMMIN model of the TraI shown in 
volumetric representation.  D, DAMMIN model of TraI superimposed with the atomic 
structures of the four structural domains of TraI (blue, the crystal structure of the relaxase 
domain 1-306, PDB entry 1P4B; yellow, the homology model of the RecD-like domain I 
310-844, from this work; pink, a homology model of the RecD-like domain II 845-1476, 
from this work; green, the crystal structure of TraI 1476-1628, PDB entry 3FLD).  
 
Figure 1.14   Model of TraI association with a dsDNA-ssDNA junction. The relaxase 
domain is shown in blue, the RecD-like domain I in yellow, the RecD-like domain II in pink, 
the C-terminal domain (CTD) in green. The two strands of dsDNA are colored in orange and 
dark green. The four sub-domains (N-terminal domain (NTD), 1A, 2A and 2B) of RecD-like 
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domain I and the five sub-domains (N-terminal domain (NTD), 1A, 2A, 1B and 2B) of 
RecD-like domain II are shown and labeled. The known NTP binding site is highlighted in 
red. In this model, the 5’ ssDNA overhang binds to the ssDNA binding groove mainly 
formed by RecD-like domain I and RecD-like domain II. The 5’ end is either free or 
covalently attached to the relaxase domain (51). The 3’ ssDNA tail is not bound by TraI. The 
dsDNA-ssDNA junction contacts subdomain 1B, or the ―pin‖ domain, of RecD-like domain 
II 
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1.6  Figures and Tables  
Table 1.1  Sequences of DNA oligomers used in this study. 
FL-T17 6FAM-5’-TTTTTTTTTTTTTTTTT-3’ 
25-mer  5’-CACTGACCGTCTGACTGCGATCCGA-3’ 
39-mer 5’-TCGGATCGCAGTCAGATGGTAAGAGAGACGCATAGATGC-3’ 
45-mer 5’GCGAACTGTCGAGTCGGCATCCGGATCTAGGGTAACCGGTACTGC-3’ 
51-mer 
5’TCGGATCGCAGTCAGATGGTAAGAGAGACGCATAGATGCTGAGTGA
GAGAT-3’ 
63-mer 
5’TCGGATCGCAGTCAGATGGTAAGAGAGACGCATAGATGCTGAGTGA
GAGATGCTCAGGTACAG-3’ 
FL-
dsDNA15 
6FAM-5’-TCG GAT CGC AGT CAG-3’ 
dsDNA9 5’-TCG GAT CGC-3’ 
dsDNA11 5’-TCG GAT CGC AG-3’ 
dsDNA15 5’-TCG GAT CGC AGT CAG-3’ 
dsDNA19 5’-TCG GAT CGC AGT CAG ACG G-3’ 
dsDNA21 5’-TCG GAT CGC AGT CAG ACG GTC-3’ 
dsDNA23 5’-TCG GAT CGC AGT CAG ACG GTC AG-3’ 
dsDNA27 5’-TCG GAT CGC AGT CAG ACG GTC AGT GAC-3’ 
 
6FAM, or 6-carboxyfluorescein, is a fluorescent probe that is covalently attached to the 5’ 
end of DNA oligomers. The subscript indicates the length of the DNA oligomer. For a 
double-stranded DNA (dsDNA) oligomer, the sequence of the complementary strand is not 
shown.  
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Table 1.2  ATPase activities of different TraI constructs 
 
 
kcat (S
-1
) 
Km,ATP 
(mM) 
kcat/Km,ATP 
(mM
-1
 S
-1
 ) 
Relative kcat /Km,ATP 
(%) 
WT 506 ± 25 1.6 ± 0.2 316 ±  26 100 
284-821 0.014 ± 0.001 0.7 ± 0.08 0.02 ± 0.003 0.006 ± 0.001 
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Table 1.3  Thermodynamic parameters of TraI binding to ssDNA oligomers of length 
ranging from 19 to 31 nucleotides in standard DNA binding buffer at 25 
o
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T19 T21 T23 T25 T27 T29 T31 
n 1 1 1 1 1 1 1 
KN×10
7
 (M
-1
) 0.9 ± 0.1 1.6 ± 0.1 2.5 ± 0.1 2.6 ± 0.3 6.2 ± 0.3 10 ± 1 12 ± 1 
Kint×10
7
 (M
-1
) N/A N/A N/A 2.6 ± 0.3 2.1 ± 0.1 2.1 ± 0.1 1.8 ± 0.5 
n, stoichiometry; KN, macroscopic binding constant; Kint, intrinsic binding constant; N/A, not applicable 
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Table 1.4   Thermodynamic parameters of TraI binding to dsDNA oligomers ranging 
from 9- to 27-mer in buffer A at 25 
o
C 
 
 
dsDNA9 dsDNA11 dsDNA15 dsDNA19 dsDNA23 dsDNA27  
n 1 1 1 2 2 2  
Kint ×10
5
 (M
-1
) 9.9 ± 7.9 4.7 ± 0.2 5.1 ± 0.2 5.2 ± 0.5 6.2 ± 0.3 5.4 ± 0.4  
ω N/A N/A N/A 18.1± 3.8 38.6 ± 7.7 14.8 ± 2.2  
n, maximum stoichiometry; Kint, intrinsic binding constant; ω, cooperativity parameter;  
N/A, not applicable 
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Table 1.5   Macroscopic binding constants of different TraI constructs to FL-dsDNA15 
in standard DNA binding buffer at 25
 o
C 
 
 
TraI constructs KN × 10
6
 (M
-1
) 
1-1756 1.6 ± 0.1 
1-1476 0.78 ± 0.7 
1-858 1.1 ± 0.1 
1-330 < 0.02 
302-1756 0.08 ± 0.01 
KN, macroscopic binding constant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 1.1    Binding of nucleotides to TraI 284-821  
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Figure 1.2   The stoichiometry of TNP-ATP binding to full-length TraI 
 
 
 
 
 
 
 
 
A 
B 
 46 
 
Figure 1.3   The ATPase and GTPase activities of TraI 284-821  
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Figure 1.4 Sequence alignment of TraI orthologs 
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Figure 1.5    The role of R446 in the ATPase activity of TraI 
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Figure 1.6      Schematic representations of the domain organization of 
TraI and the TraI constructs used in this study 
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Figure 1.7   Determination of the stoichiometry of ssDNA binding by TraI 
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Figure  1.8    Determination of binding parameters for TraI binding to ssDNA 
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Figure 1.9     Determination of stoichiometry and binding parameters for 
TraI binding to dsDNA 
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Figure 1.10   Identification of the location of the dsDNA binding site 
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Figure 1.11     ADP and AMPPNP increased TraI affinity for ssDNA 
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Figure 1.12    The role of ionic strength and base specificity in TraI DNA binding 
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Figure 1.13    Solution structure of TraI 
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Figure 1.14     Model of TraI association with a dsDNA-ssDNA junction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 2. Structural and functional studies of Arabidopsis thaliana protein arginine 
methyltransferase 10 (PRMT10) 
(This chapter has been submitted to EMBO J) 
 
2.1 Introduction 
Protein arginine methyltransferases (PRMT) are a family of enzymes that catalyze 
the transfer of methyl groups from S-adenosylmethionine (SAM) to arginine residues of 
target proteins (56). As a ubiquitous post-translational modification in eukaryotes, 
arginine methylation plays essential roles in many biological processes, such as signal 
transduction, chromatin remodeling, RNA processing, gene transcription, DNA repair 
and cellular transport (56-60). The dysfunction of PRMTs have been correlated with the 
development of cancer as well as autoimmune, cardiovascular, pulmonary and neuro-
developmental diseases (61-67). The PRMTs are mainly classified as type I (PRMT1, 3, 
4, 6, 8) or type II enzymes (PRMT5, 7 and FBXO11) (56) . Type I and type II PRMTs 
both catalyze the production of ω-NG-monomethylarginine, but they differ in the 
production of dimethyl derivatives. Type I enzymes specifically produce asymmetric ω-
N
G
,N’G-dimethylarginine, while type II enzymes only produce symmetric 
dimethylarginine (68).  
While the PRMTs have a relatively conserved catalytic core, they exhibit 
remarkable variations in the sequences N-terminal to the catalytic core. Indeed, the most 
N-terminal regions of the various enzymes (the ―N-terminal additions‖) are divergent in 
sequence and been demonstrated to be important for the substrate specificity. For 
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example, the zinc-finger domain within the N-terminal addition of PRMT3 is essential 
for its recognition of RNA-associated targets (69). Structural studies reveal that the 
catalytic core of PRMTs has a three-domain architecture: an N-terminal SAM binding 
domain, a central dimerization domain and a C-terminal β-barrel domain (70). The main 
substrate binding site is located in the cleft formed between the SAM binding domain and 
the β-barrel domain (71, 72). As a conserved feature of PRMTs, dimerization has been 
established to be essential for the methyltransferase activities of various PRMTs (71, 72).  
Disruption of dimer formation can cause the loss of SAM binding (72), although the 
underlying mechanism of this impact on enzyme function remains unclear. 
PRMT methyltransferase activity is regulated by several features of the target 
protein. The local sequence of the methylation site is one of the major determinants (73, 
74). PRMT-catalyzed methylation typically occurs within glycine and arginine rich 
motifs (or GAR motifs), such as ―RG‖, ―RGG‖ and ―RXR‖ (75), but there are exceptions 
to these rules (74). The activity of PRMTs can also be affected by the sequences distal to 
the methylation site (76) and by protein binding partners  (77, 78). Circumstantial 
evidence has suggested that PRMTs often form complexes with other proteins in vivo, 
and that these proteins impact subcellular location and substrate recognition (79, 80). 
PRMT10 is a plant-specific type I PRMT that plays an essential role in the 
regulation of flowering-time in Arabidopsis thaliana (81). Genetic disruption of PRMT10 
causes late flowering by up-regulating the transcription of FLOWERING LOCUS C 
(FLC). Biochemical studies showed that PRMT10 can specifically methylate arginine-3 
of histone H4 (H4R3) and arginine-3 of histone H2A (H2AR3) in vitro, and preferentially 
produces asymmetrical dimethylarginines (81). However, the physiological substrates of 
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PRMT10 have remained unknown. Besides PRMT10, eight other PRMTs have been 
identified in the Arabidopsis thaliana genome, including PRMT1a, PRMT1b, PRMT3, 
PRMT4a, PRMT4b, PRMT5, PRMT6 and PRMT7. These PRMT paralogs likely have 
diverse properties in cellular location, substrate specificity and protein-protein interaction 
(56).  
In this work, we report the first crystal structure of PRMT10 in complex with a 
product of its enzymatic reaction, S-Adenosylhomocysteine (SAH). This structure 
provides insights into how PRMT10 interacts with peptides, and reveals numerous 
structural features likely to confer unique substrate specificity to PRMT10, including the 
role of the PRMT10 N-terminal addition in the enzyme function. Our studies also show 
that PRMT10 exists predominantly in a dimeric state in solution, and disruption of 
dimerization cause the loss of activity. Finally, we characterize the impact PRMT10 
dimerization has on enzyme motion using molecular dynamics (MD) simulations. Our 
results highlight distinct differences between PRMT10 and other structually-
characterized PRMTs, but also suggest that motions may be a conserved element of 
PRMT function.  
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2.2 Materials and methods 
Cloning, expression and purification of PRMT10 
The expression plasmids encoding wide-type Arabidopsis thaliana PRMT10 (1-
383) and its various mutants and related constructed were created using the standard 
ligation-independent cloning techniques, as described by Stols et al. (20). All expression 
plasmids used in this study were sequence verified. The N-terminally 6×His-MBP-tagged 
PRMT10 was overexpressed in Escherichia coli BL21-CondonPlus (DE3) RIPL 
(Stratagene). The cells were grown at 37
 o
C to an OD600 of 0.6 in Luria-Bertani medium 
containing 50 μg/mL chloramphenicol and 50 μg/mL ampicilin. Protein expression was 
induced by the addition of isopropyl β-D-1 thiogalactopyranoside (IPTG) to a final 
concentration of 0.1 mM and the culture was grown for another 16 h at 18 
o
C. The 
harvested cells were resuspended in buffer A (50 mM Na phosphate pH 7.4, 50 mM NaCl 
and 20 mM imidazole) supplemented with 0.5 mM EDTA, 0.1% Triton X-100, 1 mM 
phenylmethylsulphonyl fluoride (PMSF), one tablet of a protease inhibitor cocktail 
(Roche), and 1 mg/mL lysozyme. After 45 min of incubation on ice, the resuspended 
cells were sonicated on ice for 3 min and the lysate was centrifuged at 50,000 × g for 60 
min at 4 
oC.  The supernatant was passed through a 0.2 μm filter (Millipore) and then 
loaded onto a 5 mL high performance HisTrap
TM
 column (GE Life Sciences), 
equilibrated with buffer A. The column was washed with 100 mL buffer A to remove 
nonspecifically bound proteins; the bound protein was then eluted with buffer B (50 mM 
Na phosphate pH 7.4, 50 mM NaCl and 250 mM imidazole). The elutant was loaded onto 
a HiPrep
TM
 26/10 desalting column (GE Healthcare Life Sciences) equilibrated with 
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buffer C (20 mM Tris-HCl pH 8.0 and 150 mM NaCl), and the protein fractions were 
collected. To remove the His-MBP tag, TEV protease was added into the pooled protein 
fractions with a ratio of 1:100 (w/w) TEV to PRMT10.  After 12 hr of incubation at 4
 o
C, 
the mixture was reloaded onto 5 mL high performance HisTrap
TM
 column (GE Life 
Sciences), equilibrated with buffer A. The flow-through fractions were collected and 
concentrated in a Centricon YM10 (Amicon) concentrator. Concentrated protein was 
loaded on a HiLoad
TM
 16/60 Superdex 200 column (GE, Life Sciences) equilibrated with 
sizing buffer (20 mM Tris-HCl pH 7.5, 250 mM NaCl, 5% Glycerol). PRMT10 
containing fractions were concentrated, flash frozen in liquid nitrogen and stored at -80 
o
C.  Purified protein was >95% pure by SDS-PAGE.   
Crystallization, data collection, structure determination, and refinement  
Diffraction-quality crystals of PRMT10 (residues 11-383)-SAH complex were 
obtained by the hanging-drop vapour-diffusion method at 22 
o
C, with the mother solution 
containing 0.1 M Tris-HCl pH 7.6, 2.3 M Na2HPO4 and 100 mM arginine. Crystals grew 
to the size of 250 × 200 × 50 μm in approximately 10 days. Since flash-frozen crystals 
diffracted poorly and could not be used for structural determination, diffraction data were 
collected from warm-mounted crystals to 2.6 Å resolution using a Rigaku X-ray 
generator MicroMax-007HF. Data from four different crystals were reduced and merged 
using the program HKL2000 (82) (Table 2.1). Data quality was examined using the 
program PHENIX (83). The structure was determined in space group P21 by molecular 
replacement using the program PHENIX (83). The crystal structure of rat PRMT3 (PDB 
entry, 1F3L), processed using the program chainsaw of the CCP4 package (84), was used 
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as the template for molecular replacement. Due to the salient difference between 
PRMT10 and PRMT3 in the sequence of the dimerization arm, the dimerization arm of 
PRMT3 (residues 370-399) was not incorporated into the template. Since 
psudomerohedral twinning (approximately 50%) was detected with the crystals used for 
the structure determination, least square twin refinement was performed using the 
program PHENIX. The structural model was further built manually using the program 
Coot (85), and refined using the program PHENIX.  
Methyltransferase assay 
In vitro methyltransferase assays were performed as described by Cao et al. (81). 
The reaction mixture contained 20 mM Tris-HCl pH 8.0, 4 mM EDTA, 1 mM DTT, 0.5 
mM PMSF, 4 μM S-[Methyl-3H] Adenosyl-L-methionine (Perkin Elmer [NET155]) and 
indicated concentrations of PRMTs and substrates. After being incubated for 5 hr at 30 
oC in a total volume of 20 μl, the reaction mixtures were separated on a 15% SDS-PAGE 
and stained with Commassie blue. The gel was then treated with Amplifier (Amersham 
Biosciences), dried and exposed to Kodak Biomax MS film at -80 
o
C.   
Dynamic light scattering (DLS) 
The hydrodynamic radii of various PRMT10 constructs were measured by a 
DynoPro instrument (Wyatt Technology Corporation). All samples and buffers (20 mM 
Tris-HCl pH 7.5, 100 mM NaCl, 0.5 mM EDTA) were filtered through 0.2 μM filters 
(Millipore) or centrifuged at 17,000 × g at 4 
o
C for 30 min before measurement. Three 
replicates were performed for each sample. The hydrodynamic radii and molecular 
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weights of PRMT10 samples were estimated using the assumption of globular protein 
shape.  
Molecular dynamics (MD) simulation 
MD simulations of PRMT10 were performed using the AMBER 2003 force field 
(86) as described previously (87). All production runs were generated using the PMEMD 
module of Amber 9.0 (88) with a 2 fs time step. The topology and parameter files were 
created using the LEaP program within AMBER (88). To maintain charge neutrality, the 
protein molecule was surrounded by a truncated octahedron of water and sodium ions in 
the simulation system. Electrostatic interactions were calculated using the particle-mesh 
Ewald algorithm (89) with a cutoff of 10 Å applied to Lennard-Jones interactions. Energy 
minimization was conducted using the SANDER package within AMBER (88). 
Equilibration consisted of 20 ps of constant volume conditions with heating from 100 to 
300 K and subsequent 100 ps of constant temperature conditions.  
Simulation results were analyzed by the PTRAJ package in AMBER (88). The 
pair-wise correlation coefficient, Cij, was calculated between the α-carbons of two 
residues as described by Sharma et al. (90). When the two residues i and j move in a 
correlated fashion (the angle between the motion of i and j is less than 90
 
º), 0<Cij≤1; 
when they move in an anti-correlated way (the angle between the motion of i and j is 
more than 90
 
º but less than 180
 
º), -1≤Cij<0; finally, when they move in a non-correlated 
manner (randomly), Cij=0. The more positive the value of Cij is, the smaller the angle 
between the motion of the two residues is. Single-linkage clustering analysis was 
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performed to identify groups of residues that move in a correlated or anti-correlated 
fashion, as described by Leese et al. (91).  
2.3 Results 
Crystal Structure of the PRMT10-SAH Complex 
The structure of Arabidopsis thaliana PRMT10 (residues 11-383) in complex 
with SAH was determined in space group P21 by molecular replacement and 
subsequently refined to 2.6 Å resolution (Table 2.1). Four PRMT10-SAH complexes 
were observed per asymmetric unit. The crystals used to solve the structure contain 
nearly 50% pseudomerohedral twinning as indicated by the L-test and Britton plot carried 
out by the program PHENIX (83). Notably, the β angle (89.98o) of the unit cell is very 
close to 90
o
. Consequently, the diffraction data could also be reduced into the 
orthorhombic space group P222 and its derivatives. Serious violations of systematic 
absences were observed, however, in space groups P212121, P21212, P2221. Consequently, 
molecular replacement was only performed in the space group P222. As predicted by the 
Matthew’s coefficient, two monomers were identified in each asymmetric unit. All 
solutions in space group P222, however, were finally rejected owing to the presence of 
significant main-chain clashes during crystal packing. Taken together, these results 
indicated that P21 was the correct space group and pesudomerohedral twinning was 
present. The data were detwinned using the twining refinement function of the program 
PHENIX (83).  No violations in systematic absences for P21 were observed, and the 
structure was determined and refined with confidence in this space group (Table 2.1).  
The N-terminal twenty residues of this PRMT10 construct (residues 11-30) were 
missing from the structure due to lack of electron density. PRMT10 exhibits three 
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sequentially folded domains, an N-terminal SAM binding domain (residue 31-173), a 
central dimerization arm (residues 187-235), and a C-terminal β-barrel domain (residues 
174-185 and residues 238-383) (Figure 2.1A & 2.1B). The SAM binding domain is 
composed of two N-terminal helices (αX & αY, residues 31-50) followed by a classical 
Rossman fold (residues 51-173) consisting of five α helices (αZ, αZ’, αA, αB, αD) and 
five β strands (β1 to β5). The consensus Rossman fold has been observed in other known 
SAM-dependent methyltransferases (92, 93), while the two N-terminal helices (αX & 
αY) are unique to PRMTs (71). The β-barrel domain, forming close contacts with the 
SAM-binding domain at one end of its barrel, harbors ten β-strands (β6 to β15) and two 
short α-helices (αH and αI). The dimerization arm, exhibiting a helix-turn-helix fold, is 
inserted in between β6 and β7 of the β-barrel domain and protrudes from the main body 
of the protein. Sequence analysis reveals four PRMT signature motifs in PRMT10 
(Figure 2.2). Motif I (YFxxY) and Motif II (DVGxGxG) are directly involved in the 
binding of cofactor SAM. Motif III (SExMGxxLxxExM), harbors two critical catalytic 
residues E143 and E152.  Mutation of any of these two residues completely disrupted the 
methyltransferase activity of PRMT10 (data not shown). Motif IV (or the THW motif) is 
the most highly conserved sequence among PRMTs and directly involved in the 
formation of the active site. Disruption of motif IV is accompanied with complete loss of 
the methyltransferase activity of PRMT10 (data not shown).  
The structure of PRMT10 (residues 31-383) exhibits a similar overall fold when 
compared to other known PRMT structures, sharing, for example, 1.8 Å root-mean-
square deviation over 245 Cα positions with PRMT1 (residues 41-354). However, a 
strikingly unique feature of PRMT10 is its dimerization arm, consisting of two straight 
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anti-parallel α-helices, which is significantly longer (41 Å) than that of other PRMTs of 
known structure (e.g., PRMT1, 22 Å; PRMT3, 22 Å; CARM1, 34 Å; REFs) (Figure 
2.1C). PRMT10 also differs from other PRMTs in two loop regions of the β-barrel 
domain (Figure 2.1C). Sequence alignment indicates that these loops are relatively 
conserved among PRMT10 orthologs (Figure 2.8), but highly divergent among PRMT 
paralogs (Figure 2.2). Loop I is located close to a conserved substrate binding site of 
PRMTs (see below). Acidic residues in Loop II have been shown to be important for the 
interaction of PRMT1 with its substrates (94).  
PRMT10 Active Site 
In the PRMT10-SAH complex, SAH binds to a deep pocket formed by the three 
N-terminal α-helices (αX, αY and αZ) and the carboxyl ends of the parallel β-strands (β1 
to β5) (Figure 2.1D). Most of the residues involved in SAH binding are highly conserved 
among type I PRMTs (Figure 2.2), indicating that members of the type I PRMT family 
likely share similar mechanisms in cofactor binding and catalysis. Hydrogen bonding 
plays a major role in the interaction of PRMT10 with SAH, with six hydrogen bonds 
formed between PRMT10 and all three moieties of SAH (adenine, ribose and methioine). 
R54 of the helix αZ forms bifurcated hydrogen bonds with the terminal carboxylate group 
of the methionine moiety. For the ribose moiety, hydrogen bonds are observed between 
the two hydroxyl groups and the side chains of E100 of strand β2 and Q45 of helix αY. 
The adenine group is recognized by the E129 from the loop between β2 and β4. In 
addition to hydrogen bonding, the main-chains of the glycine rich loop (Motif II) and the 
side-chains of seven other residues (A101, V128, F36, M154, S157, Y35 and Y39) 
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contact SAH through van der Waals forces. Given the small difference between the 
chemical structure of cofactor SAM and its derivative SAH, it is expected that SAM 
binds to the active site in a manner similar to that observed here for SAH. 
PRMT10 Dimer  
In the crystal structure, PRMT10 forms a ring-like homodimer through the 
interaction between the dimerization arm (αE-loop-αG) of one monomer and the outer 
surface (αY, αZ, αA & αD) of the SAM binding domain of the other monomer (Figures 
2.3A & 2.3B). The active sites are located at the periphery of this central cavity. As 
observed in other PRMTs, hydrophobic interactions play a major role in the formation of 
PRMT10 dimers. Significant conservation was maintained in the residues on the surface 
of the SAM binding domain that form the dimer interface, but not in the residues that 
form the dimerization arm (Figure 2.4). Hydrogen bonding is also observed on the dimer 
interface, with the side-chains of Q90 and N115 forming hydrogen bonds with the main-
chains of G215 and D217 respectively (Figure 2.3C). The hydrogen bonding between 
N115 and D217 are highly conserved among PRMTs (Figure 2.2), highlighting its 
importance for dimer formation. Another conserved residue on the dimer interface is 
G215, whose small side-chain is apparently favorable for the formation of the sharp turn 
at the tip of the dimerization arm.  
Notably, due to the longer dimerization arm, the central cavity of PRMT10 is 
significantly larger than those of other PRMTs of known structure (Figure 2.5).  PRMT10 
creates a cavity 15x13 Å, while those of PRMT1, PRMT3 and CARM1 exhibit cavities 
of 8x12, 8x13 and 8x11 Å, respectively (Figure 2.5).  The longer ―vertical‖ distance as 
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depicted in Figure 2.5 is generated by the longer PRMT10 dimerization arm. Consistent 
with the observation in the crystal structure, our results from dynamic light scattering and 
gel filtration experiments confirmed that PRMT10 exists predominately in a dimeric state 
in solution (Table 2.2). In addition, unlike PRMT1, which dissociates into a smaller 
oligomer upon SAH binding (72), the oligomeric state of PRMT10 is independent of the 
SAH binding (Table 2.2).  
To test the role of the dimer interface observed in the crystal structure in PRMT10 
function, we designed two mutants, ∆214-218 and ∆202-225, in which different sections 
of the dimerization arm were replaced with stretches of glycine residues. Both arm 
mutants displayed wild-type level expression and stability in E.coli, suggesting that they 
are well folded. The oligomeric states of these mutants were examined using dynamic 
light scattering and gel filtration experiments (Table 2.2). Deletion of the dimerization 
arm that forms the dimer interface (∆202-225) in the crystal structure disrupted dimer 
formation. Notably, substitution of the short loop at the tip of the dimerization arm 
(residues 214-218, YGVDM) with a stretch of five glycine residues also caused the 
complete loss of dimer formation, highlighting the important role of this short loop in 
dimer formation. The role of dimerization in the methyltransferase activity of PRMT10 
was examined by measuring the activities of two arm mutants, ∆214-218 and ∆187-235, 
that are monomers in solution. Both arm mutants displayed no observable activities 
toward H2A and H4 (Figure 2.6A & 2.6B), indicating that dimerization is essential for 
the methyltransferase activity of PRMT10.  
PRMT10 Surface Electrostatics 
 70 
 
Surface charge distribution appears to be an important functional property of 
PRMTs. For example, published data has suggested that surface charges are crucial for 
the interaction with substrates and other proteins (71, 72). Figure 2.7 illustrates the 
surface charge distribution of PRMT10. As seen in other PRMTs, the surface of PRMT10 
contains numerous acidic patches, especially around the active site. However, there are 
notable differences in surface charge distribution due to the low conservation in the 
surface residues among different PRMTs (Figure 2.7). The uniquely long dimerization 
arm of PRMT10 contains ten acidic residues, which are much more than what is observed 
in other PRMTs. Another major difference is located at one end of the β-barrel domain, 
where PRMT10 has a large acidic patch formed by residues E374, E367, E336, D339 and 
E281. The acidic residue in this region has been shown to be important for the substrate 
interaction of PRMT1 (94). Due to the low sequence conservation, the surface charge 
properties of this region are highly variable among PRMTs. Such differences are likely to 
impact PRMT substrate recognition. Structural studies of PRMT1 have indicated the 
location of the substrate binding groove of this enzyme (72). Based on the location of 
acidic patches and the shape of the PRMT10 surface in light of other PRMTs of known 
structure, we have identified four putative substrate binding grooves on the surface of 
PRMT10 (Figure 2.7). Binding grooves I and II are located in the cleft formed between 
the SAM binding domain and the β-barrel domain and are directly connected to the active 
site. Binding grove III and IV lie on the surface of the β-barrel domain. Substrates can 
also enter the active site through binding groove III. A high degree of conservation is 
maintained in the residues that form binding grooves I and II (Figure 2.4 and 2.7), 
suggesting the conserved role of these two binding grooves in substrate interaction. In 
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contrast, little conservation is observed in the residues that form binding grooves III and 
IV (Figure 2.4 and 2.7). It is possible that the diversity in binding grooves III and IV may 
confer unique substrate specificities to different PRMTs. 
Increased Active Site Accessibility in PRMT10  
As already mentioned, members of the PRMT family share a consensus three-
domain architecture and form dimers using a similar mechanism. However, the relative 
orientation of the two monomers in a functional dimer significantly varies between 
different PRMTs, due to the diversity in the length and structure of their dimerization 
arms. Consequently, the dimeric forms of different PRMTs do not superimpose well. 
When we align different PRMTs based on one of their two monomers (the ―bottom 
monomers‖ in Figure 2.8A, left panel), the other monomers (the ―top monomers‖) end up 
in distinct locations. In Figure 2.8A (left panel), the top monomers of PRMT1 (cyan) and 
PRMT3 (yellow) sit right above their bottom monomers, while the top monomers of 
PRMT10 (magenta) and CARM1 (blue) swing away from the vertical direction by 35
o 
and 20
o
, respectively. The top monomers of PRMT10 and CARM1 are observed to be 
translated leftward 21 Å and 13 Å, respectively, relative to those of PRMT1 and PRMT3 
(Figure 2.8A, middle panel). Furthermore, the angles between the two monomers in a 
PRMT dimer vary significantly between enzyme orthologues, ranging from 30
o
 in 
PRMT3 to 52
o
 in PRMT10 (shown schematically in Figure 2.8A, right panel).  
The differences in the relative orientation of the two monomers in PRMT dimers, 
together with the differences in the size of the central enzyme cavities, results in the 
variations in active site accessibility across the enzymes of known structure. To provide a 
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quantitative measure of active sites accessibility for different PRMTs, we defined an 
accessibility angle, or A-angle, for each enzyme. For PRMT10, the vertex of the A-angle 
is located at the side-chain O atom of Y147 and the two rays are made by connecting the 
side-chain O atom of Y147 and the Cα atoms of H318 from monomer I and monomer II 
respectively (Figure 2.8B). Y147 is located closed to the middle of the substrate binding 
groove that runs through the active site and H318 lies at the outer edge of the monomer. 
The A-angles of other PRMTs were defined by connecting three atoms with homologous 
positions with those of PRMT10 (Figure 2.8C-E). Based on these A-angles, the active 
sites of PRMTs have diverse accessibility, with an order of 
PRMT10>CARM1>PRMT1>PRMT3.  
PRMT10 Motion  
Although dimerization has been widely shown to be essential for the 
methyltransferase activity of PRMTs, the underlying structural mechanism has remained 
unclear. Here, we have chosen to examine the impact dimerization has on the motion of 
PRMT10 using molecular dynamics (MD) simulations. Monomeric and dimeric forms of 
PRMT10 were analyzed over a 30 ns timescale. As shown in Figure 2.9, the total energy 
of each system, calculated as the sum of the kinetic and potential energy at each time 
point, was relatively constant after the first 5 ns, particularly in the last 10 ns. Therefore, 
the averages of the MD trajectories in the last 10 ns were used for the following analysis. 
The effects of dimerization on the degree of motion of PRMT10 were analyzed by 
computing the atomic position fluctuations (APFs) of Cα atoms. PRMT10 exhibits 
similar APFs in monomeric and dimeric states, except for two regions (αY-loop-αZ, 
 73 
 
residues 40-68; the dimerization arm, residues 187-235,) where dimeric PRMT10 
displays significantly lower APFs than monomeric PRMT10 (Figures 2.10A & 2.10B). 
The reduced fluctuations within these two regions likely result from their direct 
involvement in the formation of dimer interface (Figure 2.3C). Notably, the region αY-
loop-αZ (residues 40-68) is directly involved in the binding of SAH and the formation of 
substrate binding groove I. Therefore, stabilization of this region by dimerization likely 
positively impacts the binding of SAH and substrate proteins.   
 We computed normalized covariance matrices to classify the relationships 
between the motions of all residue pairs in the protein (Figures 2.10C & 2.10D). 
Normalized covariance matrices generate the residue-residue correlation coefficients 
(Cijs), which inform the relative motion between a residual pair. Based on the value of 
Cijs, the motions of all residue pairs can be classified into three groups, correlated motion 
(two residues moving toward the same direction) as indicated by Cij approaching 1, anti-
correlated motion (two residues moving toward the opposite direction) as indicated by Cij 
approaching -1, and uncorrelated motion (two residues moving with the lack of a 
dynamic relationship) with Cij values near zero. The SAM binding domain of dimeric 
PRMT10 exhibits considerably greater residue-residue correlations relative to that of 
monomeric PRMT10 (Figure 2.10C). Increased residue-residue correlations are also 
observed in several discrete regions of the β-barrel domain.   
To better understand the biological significance of residue-residue correlations, 
single-linkage clustering analysis was then conducted to identify groups of residues that 
move together (see Experimental Procedures for details). Clustering of dimeric PRMT10 
at a correlation coefficient above 0.7 resulted in five clusters, while clustering of 
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monomeric PRMT10 under the same criterion only resulted in three clusters (Figures 
2.10E & 2.10F). One notable difference between monomeric PRMT10 and dimeric 
PRMT10 lies in the SAM binding domain. Most parts of the SAM binding domain, 
except the two N-terminal helices (αX and αY) and two loop regions (L1 and L2), are 
clustered in dimeric PRMT10 (Figure 2.10G), while only helix B is self-clustered in 
monomeric PRMT10. In addition, one end of the β-barrel domain is also clustered in 
dimeric PRMT10, but not in monomer PRMT10. Our results clearly show that the SAM 
binding domain and one end of the β-barrel domain to move as a cohesive unit in dimeric 
PRMT10, but not in monomeric PRMT10. These observations provide a structural 
mechanism that explains the essential nature of PRMT dimerization for enzyme function.  
PRMT10 N-terminus in Enzyme Function 
Finally, we examined the role of the N-terminal addition (residues 1-30) in the 
oligomeric state and methyltransferase activity of PRMT10. We created three N-terminal 
deletion mutants, including ∆N10 (residues 11-383), ∆N20 (residues 21-383) and ∆N30 
(residues 31-383), and compared them to wild-type PRMT10. The oligomeric states of 
these mutants were investigated using dynamic light scattering (DLS) and gel filtration 
experiments (Table 2.2). As observed in the wide-type enzyme, all N-terminus deletion 
mutants remain as dimers in solution. Moreover, the oligomeric states of these mutants 
are SAH-independent. Together, these data suggest that the N-terminal addition does not 
impact PRMT10 dimerization.    
The methyltransferase activities of wide-type PRMT10 and three N-terminal 
deletion mutants were measured as previously described (see experimental procedures) 
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(2.5A & 2.5B). Purified calf thymus core histones, which are a mixture of histones H2A, 
H2B, H3 and H4, were chosen as the substrate. Interestingly, ∆N10 had approximately 3-
fold greater activities toward H2A relative to the wide-type enzyme. Further deletions of 
the N-terminus (∆N20 and ∆N30) do not enhance the activity over H2A. When H4 was 
used as the substrate, however, all three N-terminus mutants displayed wide-type level 
activities. In the crystal structure, helix αX (residues 32-40) plays an important role in 
cofactor bining by covering the opening of the SAM binding pocket. As expected, the 
deletion of the helix αX of PRMT10 (∆N40) caused a dramatic drop in its activity over 
both H2A and H4. Taken together, our results indicate that first ten residues of PRMT10 
impact enzyme methyltransferase activity in a substrate-dependent manner.  
Previous studies of PRMT1 have shown that the substrate sequence distal to the 
methylation site can affect its activity toward H4. Thus, we examined if the substrate 
sequence outside of the methylation site also impacts the activity of PRMT10 using 
purified full-length histone H4 and H4N1-20, a peptide covering the N-terminal twenty 
residues of histone H4. First, we found that the activity of PRMT10 on the full-length H4 
substrate was markedly higher than that on the H4N1-20 substrate (Figure 2.6C), in spite 
of the fact that 10-fold more H4N1-20 peptide was employed in these assay.  Thus, it 
appeared that the sequence outside the N-terminal 20 residues of histone H4 was 
important for the methyltransferase activity of PRMT10.  
To probe further the impact of protein regions outside the methylation site, we 
examined a glutathione-S-transferease-tagged H4 substrate. The arginine-3 methylation 
site of PRMT10 in both histone H2A and histone H4 is located at the far N-terminus of 
these proteins. To examine if a bulkly protein fused to the N-terminus of H4 would 
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impact PRMT10 activity on H4R3, we compared the methylation of histone H4 and N-
terminally GST-tagged histone H4 (GST-H4) by PRMT10 (Figure 2.6C). Our results 
show that the presence of a N-terminal GST tag reducing the activity of PRMT10 by ~2-
fold relative to untagged H4. These data indicate that PRMT10 can methylate H4R3 even 
when it is not located at the far N-terminus of this histone protein.  
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2.4 Discussion 
We present the first structure of a plant protein arginine methyltransferase, that of 
PRMT10, and highlight unique features of this enzyme, including a long dimerization 
arm and a distinctly open conformation in the catalytic dimer.  However, we also 
establish for the first time that the family of PRMTs exhibit conserved domain motions, 
particularly within the enzyme region that binds the SAM substrate that donates the 
methyl group to arginines on target proteins. Together, these data advance our 
understanding of features shared by the PRMT enzymes, which function as both 
epigenetic and non-epigenetic factors, as well as unique aspects of particular family 
members that may impact substrate preference. 
            In a functional PRMT dimer, the enzyme active sites are located at the periphery 
of a central cavity. This configuration likely impacts access of substrate proteins to the 
PRMT catalytic site. Indeed, most known methylation sites are located in disordered 
regions of substrates, and the structural flexibility around the methylation site has been 
shown to be essential for PRMT function. Comparing the PRMT dimer to that of other 
PRMTs of known structure led to the appreciation that PRMT paralogs exhibit diverse 
central cavity sizes, with an order of PRMT10>CARM1>PRMT1>PRMT3 (Figure 2.8). 
This variation mainly results from the difference in the relative orientation of the two 
monomers in a functional PRMT dimer and the difference in the size of the dimerization 
arm. Previous studies have shown that the activity and substrate specificity of PRMTs are 
directly correlated with active site accessibility (95). Thus, the more accessible PRMT10 
active site may allow this enzyme to methylate arginine residues that do not serve as 
substrates for other PRMT enzymes.  
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We show that the Arabidopsis thaliana PRMT10 enzyme functions only as a 
dimer. Although this now appears to be a feature common to all PRMTs, the precise 
mechanism of how PRMT dimerization impacts enzyme function has remained unclear. 
Our data from MD simulations on both the monomeric and dimeric forms of PRMT10, as 
well as PRMT1 and PRMT3, show that dimer formation produces coherent motions in 
key catalytic domains. PRMT dimers exhibit reduced fluctuations in the N-terminal αY-
loop-αZ region, which not only forms direct contacts with the SAM methyl donor, but 
also forms a portion of substrate binding groove I that is conserved among PRMTs. 
Furthermore, dimerization results in more correlated motions throughout the SAM 
binding domain. Previous studies have shown that oligomerization can facilitate protein-
ligand interaction by increasing the correlation in the motion of the structural elements 
involved in ligand binding. (87). Importantly, our results show that the effects of 
dimerization on the motion of PRMT10 can be generalized into other members of the 
PRMT family. Thus, we conclude that dimerization facilitates the methyltransferase 
activity of the PRMTs by producing coherent protein motions involving the SAM 
cofactor.   
Members of the PRMT family have a relatively conserved catalytic core, but 
exhibit remarkable diversity in the length and sequence of their N-terminal regions. 
Multiple lines of evidence suggest that the variations in the N-terminus diversify the 
functions of the PRMT family by modulating the substrate specificities. PRMT10 has a 
30-residue N-terminal addition, which is one of the shortest among known PRMTs. 
Secondary structure analysis predicts that the N-terminal addition of PRMT10 remains in 
a disordered state. In support of this prediction, the PRMT10 N-terminal addition is prone 
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to proteolysis (data not shown), and is not ordered in our crystal structure. Although 
PRMT1 also has a short N-terminal region (~31 residues), its length varies more among 
different PRMT1 isoforms and these variations have been shown to alter the substrate 
specificity of PRMT1 (96).  
In this work, we have established that the N-terminal addition (residues 1-10) can 
also affect the substrate specificity of PRMT10. The deletion of the N-terminal addition 
enhances the activity of PRMT10 over H2A, but does not change its activity over H4 
significantly. This variation may result from the difference in the way that H4 and H2A 
interact with PRMT10.  Based on the crystal structure of dimeric PRMT10, the 30-
residue N-terminal addition is likely located at one side of the ring and affects substrate 
binding grooves III and IV, having less or no effect on substrate binding grooves I and II. 
Our results suggest that H2A may approaches the active site through substrate binding 
groove III or IV, but H4 employs substrate binding groove I. The local sequence of the 
methylation site in H2A (SGR3GKGG) is identical to that of H4 (SGR3GKGG), 
indicating that the sequence outside the methylation site is also important for the 
interaction of PRMT with its substrates. In support of this notion, our results clearly show 
that deletion of the sequence C-terminal to the residue 20 of H4 dramatically reduced the 
methylation at arginine 3 by PRMT10. Considering that fact that PRMT10 displays 
similar activity over H4N1-20 and H4 when the concentration of H4N1-20 is 500 μM 
(data not shown), we hypothesize that the substrate sequence outside of the methylation 
site likely facilitates the methylation by enhancing the binding affinity between PRMT10 
and its substrate.  
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PRMT10 displayed comparable activities over histone H4 and N-terminally GST-
tagged histone H4 (GST-H4). In histone H4, the methylation site arginine-3 is located 
proximal to the N-terminus. Therefore, the substrate can bind to the substrate binding 
grooves in a linear structure as shown in the crystal structure of PRMT1-substrate 
complex.  However, due to the blockage of the N-terminus by GST in GST-H4, a loop 
structure has to form in order for the argnine-3 to enter the active site of PRMT10. Our 
results suggest that the proximal of the methylation site to the N-terminus is not essential 
for the methylation catalyzed by PRMT10 and the methylation site located far away from 
the ends can also reach the active site of PRMT10 by forming a loop structure. Taken 
together, these data expand our view of PRMT structure and function.  They indicate that 
while the family of enzymes share some key traits (e.g., a functional dimer and coherent 
SAM-binding domain motion), unique features of particular PRMTs, like the larger 
central cavity of the PRMT10 dimer, may lead to unique methylation patterns and even 
target substrate proteins.  
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2.5 Figure Legend 
Figure 2.1. Crystal structure of PRMT10. (A) Domain architecture of PRMT10 from 
Arabidopsis Thailian. The SAM binding domain (residues 31-174) is shown in red; the β-
barrel domain (residues 174-186, 236-383) in blue and the dimerization domain (or arm 
domain, residues 186-236) in yellow. (B) A ribbon show of the crystal structure of 
PMT10-SAH complex with labeling of secondary structure elements (helices X through I 
and β-strands 1 through 15). The bound SAH is shown as sticks and spheres. The 
structure is colored as displayed in Figure 2.1A. The start and end residues of PRMT10 
are indicated. (C) Two views of the superimposition of PRMT10 (residues 31-383, 
magenta) with rat PRMT1 (residue 41-353, cyan, PDB entry 1ORI). Structure differences 
between PRMT10 and PRMT1 (located in the dimerization domain and two loops in the 
β-barrel domain) are indicated by arrows. (D) A Stereo-view representation of SAH 
binding. The Simulated annealing omit map of SAH contoured at 1σ (colored in blue) is 
shown. Hydrogen bonds are indicated by red dashed lines. 
Figure 2.2. Structure-based sequence alignment of PRMT10 and other PRMT 
paralogs, including rat PRMT1 (PDB, 1ORI), rat PRMT3 (PDB, 1F3L), mouse CARM1 
(PDB, 3B3F) and yeast RMT1 (PDB, 1G6Q). The secondary-structure elements are 
shown across the top of the sequences. The residue numberings are shown on the right 
side. Invariant and similar residues are highlighted in black and gray, respectively. The 
SAM binding domain is colored in red; the dimerization domain in yellow; and the β-
barrel domain in blue. The four PRMT signature motifs are labeled. Residues involved in 
SAM binding and dimerization are highlighted by red and black stars respectively.  
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Figure 2.3. Dimer formation of PRMT10. (A) A ribbon show of the crystal structure of 
a PRMT10 dimer. The structure is colored and labeled as shown in Figure 2.1B. The 
location of dimer interfaces are highlighted by arrows. The dimer is formed by the 
interaction between the dimerization arm of one monomer and the outer surface of the 
other monomer. (B) Two views of a PRMT10 dimer in surface representation, with wwo 
monomers are colored in gray and pink respectively. (C) An expanded stereo-view of the 
dimer interface. Two monomers are colored as shown in Figure 2.2B. Residues involved 
in dimer formation are shown as sticks and labeled. 
Figure 2.4.  Conserved residues between PRMT10 and other PRMT paralogs, 
including rat PRMT1, rat PRMT3, yeast RMT1 and mouse CARM1/PRMT4, were 
mapped onto the structure of PRMT10. All three views are shown in surface 
representation where magenta represents residues with 100% conservation and yellow 
denotes residues with high similarity (>80% conservation). The top left view has the 
same orientation as shown in Figure 2.1B. The location of dimer interface and active sites 
are labeled.   
Figure 2.5. Surface representation of various PRMT paralogs, including rat PRMT1 
(PDB: 1ORI) (A), rat PRMT3 (PDB: 1F3L) (B), mouse CARM1 (PDB: 3B3F) (C) and 
Arabidopsis PRMT10 (D). For consistency, the sequences N-terminal to helix X 
(including helix X) are deleted from the structure.  The sizes of the central cavity of 
different PRMT paralogs are labeled.  
Figure 2.6. Methyltransferase activities of different PRMT10 constructs in vitro. (A) 
Indicated PRMT10 constructs (5 μg) were incubated with the reaction buffer containing 
10 mM Tris pH 8.0, 4 mM EDTA, 1 mM DTT and 0.5 mM PMSF, 10 μM calf thymus 
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core histones and 4 μM methyl donor S-adenosyl-L-[methyl-3H] at 30 °C for 5 hours 
(total reaction volume 20 μl). The reaction mixture was separated on a 15% SDS-PAGE 
and the autoradiograph of the gel is recorded. The experiments were performed in 
triplicate and a typical result is shown here. (B) Quantification of the results from Figure 
2.7(A). The relative activities presented here were calculated by considering the activity 
of wide-type PRMT10 over H2A as one.    
Figure 2.7. PRMT10 exhibits a uniquely open conformation. (A) Superimposition of 
PRMT10 (magenta) with rat PRMT1 (cyan, PDB: 1ORI), rat PRMT3 (yellow, PDB: 
1F3L) and mouse CARM1 (blue, PDB: 3B3F). The bottom monomers are used for the 
alignment. The left view rotates about 90
o 
along the vertical axis with respect to the view 
shown in Figure 2.2A. For clarity, the bottom monomers are not shown in the middle 
panel. The left edges of four monomers are indicated by vertical dashed lines with 
corresponding colors. The distance of the leftward translation of PRMT10 and CARM 
relative to PRMT3 are shown. The right panel is a schematic representation of the upper 
right view, with PRMT monomers shown as rectangles. The superimposed bottom 
monomers are shown and colored in white. (B)-(E) Views of the dimeric rat PRMT1, rat 
PRMT3, mouse CARM1 and PRMT10. The accessibility of the active sites was 
represented by an angle (the A-angle) whose vertex is located at the center of the central 
cavity and the two rays are made by connecting the vertex and two surface residues. 
Figure 2.8. Surface electrostatics of PRMT10. Acidic surfaces are represented in red; 
basic surfaces in blue and neutral surfaces in gray. Acidic surface residues are labeled 
and colored based on their conservation among five PRMT paralogs as indicted by the 
sequence alignment in Figure 2.2 (black, conservation≥80% ; green, 
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40%<conservation<80%; blue, 20%<conservation≤40%; unique for PRMT10, red). The 
location of putative substrate binding grooves, the active site, the dimer interface and 
helix αX are highlighted and labeled. The top left view has the same orientation as shown 
in Figure 2.1B. 
Figure 2.9. Conservation of total energy during PRMT10 simulations. Total energy, 
an indicator of the overall simulation stability, remains relatively constants during the 
course of MD simulations of monomeric PRMT10 (A) and dimeric PRMT10 (B). The 
average of the total energy is shown in a blue lines (A) and a green line (B), respectively. 
The final 10 ns of each simulation, highlighted by dashed red square, was used for 
analysis. 
Figure 2.10. Effects of dimerization on the motion of PRMT10. (A) Local fluctuation 
(B factors) of residues in dimeric and monomeric PRMT10. Major differences between 
monomeric and dimeric PRMT10 are highlighted by arrows. (B) The structure of a 
dimeric PRMT10. The two monomers are colored in blue and green respectively. The N-
terminal region αY-loop-αZ , which displayed dramatically reduced local fluctuations in 
dimeric PMT10, is  colored in magenta. Covariance analysis of dimeric PRMT10 (C) and 
monomeric PRMT10 (D). The values of residue-residue correlation coefficients range 
from blue (anticorrelated, -0.62) to red (correlated, +1.00), with non-correlated residue 
pairs colored in yellow. Schematic representations of the secondary structure 
corresponding to the residues on x-axis and y-axis are presented from left to right and 
bottom to top. (E), (F) Clustering of correlated residues in dimeric PRMT10 (E) and 
monomeric PRMT10 (F). Clusters with correlation coefficients higher than 0.7 are shown 
in different colors (other than gray) and all other regions are colored in gray. SAH is 
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shown as sticks and spheres to highlight the location of the SAM binding pocket, 
although it is removed from the crystal structures before MD simulations. (G) An 
expanded stereo-view of the SAM binding domain of Figure 2.10E, with the secondary 
structures labeled.  
Figure 2.11. Sequence alignment of PRMT10 orthologs from various plants. The 
aligned sequences include PRMT10 from A.thaliana, G.max, V. vinifera, P.trichocarpa, 
Z.mays, S.bicolor and O.sativa. The alignment was conducted using Clustal W, and then 
manually adjusted. The secondary-structure elements and residue numbering of PRMT10 
are shown across the top of the sequences, colored and labeled as shown in Figure 2.1B. 
Residues involved in SAH binding and dimer formation are highlighted by red and black 
stars, respectively. Four PRMT signature motifs are lableled.   
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2.6 Figures and Tables  
Table 2.1     Crystallographic data and refinement statistics for PRMT10 
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Table 2.2    Oligomeric states of PRMT10 mutants  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monomer 
Size (kDa)  
- AdoHcy  
 
+ AdoHcy  GF size 
(-AdoHcy)  
(kDa) 
GF size/ 
Monomer size DLS Size  
(kDa)  
DLS  Size/ 
Monomer Size   
DLS Size  
(kDa)  
DLS  Size/ 
Monomer Size  
wt  43.1  93  2.2  
 
92  2.1  79.5  1.8  
∆N10  42.1  89  2.1  
 
87  2.1   N.D.    N.D.  
∆N20  41.4  83  2.0  
 
83  2.0   N.D.    N.D.  
∆N30  40.4  74  1.8  
 
80  2.0  68  1.7  
∆214-218  42.5  111  1.3  
 
114  1.3  37.9  0.9  
∆202-225  40.8  66  1.6  
 
61  1.5  34.4  0.9  
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Figure 2.1   Crystal structure of PRMT10 
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Figure 2.2   Structure-based sequence alignment of PRMT10 and other 
PRMT paralogs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV 
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Figure 2.3     Dimer formation of PRMT10 
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Figure 2.4    Conserved residues between PRMT10 and other PRMT paralogs 
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Figure 2.5   Surface representation of various PRMT paralogs 
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Figure 2.6    Methyltransferase activities of different PRMT10 constructs 
 
\\\ 
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Figure 2.7   Surface electrostatic potential of PRMT10 
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Figure 2.8    PRMT10 exhibits a uniquely open conformation 
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Figure 2.9     Conservation of total energy during PRMT10 simulations 
 
 
 
 
 
 
 
A 
B 
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Figure 2.10     Effects of dimerization on the motion of PRMT10 
 
 
 
A 
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Figure 2.11    Sequence alignment of PRMT10 orthologs in various plants 
 
 
 
 
 
 
  
Chapter 3.  Activation of the human nuclear xenobiotic receptor PXR by the reverse 
transcriptase-targeted anti-HIV drug PNU-142721 
(This chapter has been submitted to Protein Science) 
3.1 Introduction 
            Nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs) and non-
nucleoside (or nucleotide) reverse transcriptase inhibitors (NNRTIs) are the two popular 
types of anti-HIV drugs that target RT (97). NRTIs directly bind to the catalytic site of RT 
and competitively inhibit enzyme activity, while NNRTIs bind to an allosteric lipophilic site 
adjacent to the catalytic site of the RT and function in a non-competitive manner (98). Due to 
their distinct mechanisms, NRIs and NNRTIs are commonly used together in HIV treatment 
regimen to achieve optimal efficacy (99, 100). Like other antiviral drugs, the usefulness of 
anti-HIV drugs is often compromised by mutations in the drug binding sites of HIV RT, 
which arise quickly due to the high mutation rate of the virus (101). Over the past two 
decades, the design of new drugs that can efficiently treat drug-resistant HIV has become a 
significant challenge (102). Indeed, the combinational use of multiple anti-HIV drugs with 
distinct mechanisms of action, such as the triple-cocktail treatment, has thus-far been proven 
to be the most effective anti-HIV regimen available (103).  
           A fundamental problem associated with coadministering multiple drugs is the risk of 
drug-drug interactions. Cytochrome P450 (CYP) enzymes have been shown to be centrally 
involved in such interactions due to the principal role these proteins play in eliminating 
potentially toxic xenobiotics (104). The nuclear receptor pregnane X receptor (PXR) is a 
master regulator of the expression of CYP enzymes involved in drug metabolism. PXR is the 
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primary sensor of xenobiotic stress in the liver and other first-pass tissues and can be 
activated by a structurally diverse collection of molecules including many drugs (105, 106). 
Like other nuclear receptors, PXR contains a DNA binding domain (DBD), a ligand-binding 
domain (LBD), and a flexible linker domain (106). The PXR-LBD consists of a three-layered 
-helical sandwich, common to nuclear receptors and a five-stranded anti-parallel-sheet, 
unique to PXR (107-112). The PXR-DBD binds specifically to the DNA response elements 
in the regulatory regions of CYP genes as a heterodimer with the retinoid X receptor (RXR) 
(105). Upon activation by ligand binding to the LBD, PXR recruits coactivators that facilitate 
the formation of the transcriptional initiation complex and the expression of CYP gene 
products  (105).  Coactivator proteins bind to the activation function 2 (AF-2) region of the 
PXR-LBD using a surface formed, in part, by the C-terminal AF helix in the receptor (113). 
PNU-142721 was first identified as a broad-spectrum second-generation NNRTI that 
demonstrated potent efficacy against various type I HIV mutants resistant to first-generation 
antivirals like delavirdine and zidovudine (Figure 3.1) (114). Despite its promising in vitro 
performance, studies showed that PNU-142721 causes strong drug-drug interactions. Here, 
we test and validate the hypothesis that PNU-142721 causes drug-drug interactions by 
activating PXR. We also elucidate the structure basis for PNU-142721 mediated PXR 
activation by solving the crystal structure of PXR-LBD in complex with PNU-142721. 
 
 
 
 
3.2 Materials and methods 
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Protein Expression and Purification The human PXR-LBD (residues 130-434) was 
coexpressed with an 88-amino acid fragment of human steroid receptor coactivator 1 (SRC-
1) (623-710) in E. coli  and purified as described previously (111). Purified hPXR-LBD was 
concentrated to 3 mg/mL in buffer containing 20 mM Tris-HCl (pH 7.8), 250 mM NaCl, 5 
mM DTT, 2.5 mM EDTA  and 5% Glycerol (v/v) using a Centri-prep 30K unit (Amicon) in 
the presence of 20-fold molar excess PNU-142721. Purified protein was flash-frozen using 
liquid nitrogen and stored at -80 
o
C. 
Crystallization, Data Collection and Structural Determination. The hPXR-PNU142721 
complex was crystallized by hanging-drop vapor diffusion at room temperature against 50 
mM imidazole (pH 7.8) and 16% 2-propanol (v/v). Crystals were handled for cryoprotection 
as described previously (111). Data collection was conducted at SER-CAT at the Advanced 
Photon Source in Argonne National Labs (Beamline 22-ID). Diffraction data were indexed, 
integrated and scaled using HKL2000 (115). The structure of hPXR-PNU142721 complex 
was determined by molecular replacement with the MolRep module of the CCP4 suite (116, 
117) using the crystal structure of the apo PXR as the search model. Clear rotational and 
translational solutions were obtained in space group P43212. The structure was manually 
adjusted using WinCoot 3.1 (118), and refined using the Refmac module of CCP4 (119), 
with 10% of the reflections set aside for Rfree validation prior to any structural refinement.  
Simulated annealing omit map was generated using the program CNS (120).  Graphica; 
figures were created using Pymol (121) 
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3.3 Results 
PXR-PNU142721 Complex Crystal Structure  
To understand the structural basis of receptor activation by this potential therapeutic 
lead, we determined the crystal structure of the human PXR-LBD in complex with PNU-
142721. One protein-ligand complex was observed in each asymmetric unit. The structure 
was determined by molecular replacement in space group P43212 and refined to 2.8 Å 
resolution (Figure 2A and Table 3.1). The PXR-LBD in this complex consists of a three-
layered α-helical sandwich (α1/ α 3, α 4/ α 5 /α8, and α7/ α10) common to nuclear receptors 
and a five-stranded anti-parallel β-sheet unique to PXR (Figure 3.2A). Three regions located 
adjacent to the ligand-binding pocket (the loops 176-198 and 309-315, as well as residue 
217) are disordered and not built in the final model (Figure 3.3). The region between residues 
176 and around 198 have been reported to be disordered in other PXR-LBD structures 
resolved to date (107-113). The PXR-PNU142721 complex exhibits the same overall fold 
observed in previous PXR structures, sharing, for example, 0.22 Å root-mean-square 
deviation over 254 Cα  positions with the structure of the unliganded PXR-LBD (111).   
PNU-142721 Binding to PXR-LBD  
A 2.8 Å simulated annealing omit map contoured at 2.5 σ was used to identify the 
electron density for PNU-142721, which binds to the PXR ligand-binding pocket in a single 
orientation (Figure 3.2B). PNU-142721 forms van der Waals contacts with the side chains of 
fourteen residues that line the ligand-binding pocket (Figure 3.2C). In addition, the side-
chain amine group of Gln-285 forms a 3.3 Å weak hydrogen bond with the nitrogen atom of 
the furopyridine ring of PNU-142721 (Figure 3.2C). As observed in other complexes, van der 
Waals contacts play a principal role in stabilizing PNU-142721 within PXR’s ligand-binding 
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pocket. Phe-288 forms a parallel aromatic stacking interaction with the furopyridine ring of 
PNU-142721, while Trp-299 and Tyr-306 form edge-to-face aromatic stacking contacts with 
the same ligand ring. The pyrimidine ring of PNU-142721 forms van der Waals interactions 
with the side chain of eleven residues, including a 3.6 Å interaction with Met-425 and a 5.0 
Å interaction with Phe-429, which are located on AF of the PXR AF-2 surface. These 
interactions likely help to stabilize the active conformation of the AF-2 surface for 
coactivator binding.  
PNU142721 Metabolite Binding to PXR-LBD 
PNU-173575, a thiomethyl metabolite of PNU-142721, is a more potent activator of 
PXR than the unmodified compound (unpublished data from Dr. Evan Smith) (Figure 3.1B). 
As shown in Figure 3.1, the only difference between these two compounds is that the chloro 
group on the pyrimidine ring of PNU-142721 is replaced by a thiomethyl group in PNU-
173575.  To understand why this small change improves PNU-173575 PXR activation, we 
modeled PNU-173575 into PXR’s ligand-binding pocket using the structure of PNU142721 
as a template (Figure 3.4). To accommodate PNU-173575, the side chain of Leu-411 and 
His-407 were shifted by favored rotamers by alterations of 100.3
o
 and 88.5
o
, respectively 
(Figure 3.4). Although the rotamer change in His-407 is likely to cause the loss of a 4.8 Å 
van der Waals contact between the ligand and PXR, two new van der Waals contacts are 
observed between the thiomethyl group and the side chain of residues that are located on the 
AF of the PXR AF-2 surface, including a 3.9 Å contact with Met-425, and a 4.1 Å contact 
with Phe-429.  Thus, these new van der Waals contacts likely explain the improved PXR 
activation of PNU-173575, as they are better able to stabilize the active conformation of 
receptor’s AF-2 surface. 
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Modeling of the structure of rat PXR-LBD in complex with PNU-142721 
As shown in Figure 3.3, PNU-142721 can induce PXR-mediated CYP3A expression 
in rats. Due to the relatively high sequence similarity (76% identity) shared between the rat 
and human PXRs, the rodent receptor is expected to have a structure highly analogous to 
human PXR. To understand rat PXR activation by PNU-142721, we modeled the structure of 
the ligand-binding pocket of rat PXR based on the structure of human PXR. The following 
five residues that interact with PNU-142721 in human PXR were altered to the 
corresponding residue (listed second) in the rat sequence: Leu209Met, Met243Leu, 
Met246Val, Gln285Ile and His407Gln (Figure 3.5). Because they are largely conservative 
with respect to amino acid type, no significant change in the interaction between PNU-
142721 and the PXR-LBD was observed in this modeled binding pocket.  Indeed, PNU-
142721 still forms fourteen van der Waals contacts with residues that line the ligand binding 
pocket of rat PXR. Thus, for this particular lead scaffold, rat PXR served as an excellent 
model for potential activation of human PXR.  
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3.4 Discussion 
As the use of anti-HIV drug cocktails becomes increasingly necessary, dangerous 
drug-drug interactions may emerge as a major challenge in the antiretroviral field. Studies 
showed that potent HIV-1 RT inhibitor PNU-142721 produced drug-drug interactions, 
although the underlying mechanisms remained elusive. It has been shown that PNU-142721 
activates the nuclear xenobiotic receptor PXR in a concentration-dependent manner and 
PNU-173575, the metabolite of PNU-142721, is a better PXR-agonist than PNU-142721 
(unpublished data from Dr. Evan Smith). Altogether, these results established that PNU-
142721 is a efficacious PXR agonist and it likely causes drug-drug interactions by activating 
PXR. 
We elucidated the crystal structure of the PXR-LBD in complex with PNU-142721.  
The mechanism of ligand-induced PXR activation has been well studied by x-ray 
crystallography and other techniques. To activate PXR, a ligand needs to binds to the ligand-
binding pocket of PXR and form direct interactions with the αAF helix, thereby stabilizing 
the AF-2 surface in the active conformation (106). Due to the large size and flexibility of the 
PXR’s ligand binding pocket, however, it has been difficult to predict the exact binding mode 
of a novel ligand in PXR’s ligand binding pocket by known PXR structures, although recent 
studies have demonstrated progress in this regard (122). Our PXR-PNU-142721 complex 
crystal structure reveals that van der Waals interactions play a major role in stabilizing the 
interaction between drug and receptor (Figure 3.2C). PNU-142721 forms van der Waals 
contacts with fourteen residues in PXR’s ligand-binding pocket, which covers all of five 
ligand-binding hot spots recently identified by Ngan et.al, indicating a strong affinity 
between PNU-142721 and PXR. As in previous PXR-ligand structures, Gln-285 is found to 
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form a hydrogen bond with the ligand, indicating its conserved role in ligand interaction. 
PNU-142721 forms direct van der Waals contacts with Met-425 and Phe-429, which are 
located on the αAF helix. The contact with Met-425 has been commonly observed in 
previous published PXR-ligand structures, while the contact with Phe-429 only appears in 
the PXR-estradiol structure to date.  
The crystal structure of the PXR-PNU142721 complex was then used to examine two 
recent observations: 1) the thiomethyl metabolite PNU-173575 exhibits improved PXR 
activation relative to PNU-142721; and 2) PNU-142721 is also an agonist for rat PXR 
(unpublished data from Dr. Evan Smith). First, we found that the modeled structure of PNU-
173575 in PXR’s ligand binding pocket indicates that 173575 can bind to PXR in a similar 
way as PNU-142721. By means of the longer and more hydrophobic thiomethyl group, PNU-
173575 appears capable of forming improved interactions with the αAF helix, and thereby 
stabilize the AF-2 surface in an active conformation. Second, the ligand-binding pocket of rat 
PXR can be modeled simply by mutating five residues in human PXR to their counterparts in 
rat PXR. Despite several changes in relevant residues, key ligand interactions are conserved 
between human PXR and rat PXR, indicating that rat PXR can bind PNU-142721 in a similar 
way to human PXR. Our results reinforce the hypothesis that, in this particular case, the rat 
could be used as a good model for the prediction of potential drug-drug interaction in human.  
If one wanted to modify PNU-142721 to eliminate its activation of PXR, the crystal 
structure of the complex could be used as a guide. The van der Waals interaction between the 
chloro-group on the pyrimidine ring of PNU-142721 and the αAF helix of PXR appear key to 
the stabilization of AF-2 surface in the active conformation. Therefore, disrupting the 
interaction between PNU-142721 and the AF-2 surface could be achieved by removing the 
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chloro-group from the pyrimidine ring. However, previous studies have shown that the 
pyrimidine thioether moiety is the major anti-HIV pharmacophore of PNU-142721 (114). 
The furopyridine moiety, however, was not as important (114), and thus, it might be safer to 
disrupt the interaction between PNU-142721 and PXR by modifying this ring. As observed 
in the complex structure, the furopyridine ring of PNU-142721 interacts with five residues in 
the ligand-binding pocket including Phe-288, Trp-299, Tyr 306, His-327 and Gln-285. 
Among these contacts, the π-π interaction between the side-chain of Phe-288 and the 
furopyridine ring provide the major stabilizing forces, keeping the furopyridine ring in the 
current orientation. Disruption of this interaction by introducing a bulky group on the C2 
atom of the ligand (see Figure 3.1), which is spatially closest to Trp-299 (see Figure 3.5), 
may effectively destabilize the interaction of PNU-142721 with PXR. Either PNU-142721 or 
Trp-299 would have to move to accommodate this bulky group. Trp299 is located on four-
stranded β-sheet, which is known for its rigidity and does not change its conformation even 
upon the binding of large PXR ligands like rifampcin.  Therefore, it is not likely that Trp-299 
would adjust its position to accommodate the bulky group. Also, there is no observable space 
around Trp-299 for its side-chain to take alterative rotamers to accommodate the bulky 
group. Therefore, it would be expected that PNU-142721 might move away from Trp-299 
toward the other side of the ligand-binding pocket. This movement will break three important 
interactions between PXR and the furopyridine ring of PNU-142721, including the π-π 
interaction with Phe-288, the van der Waals interaction with Tyr-306, and the hydrogen 
bonding with the side chain of Gln-285. Although several new van der Waals interactions 
might form meanwhile, they are not likely to compensate for the losses mentioned above. 
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Taken together, the proposed modification here might mitigate PXR agonist activity by 
disrupt the binding of PNU-142721 to PXR.  
In summary, the data presented here reveal the detailed mechanism of PNU-142721-
mediated PXR activation. Using the structural model presented here, we explained why the 
metabolite PNU-173575 is a better PXR agonist and why PNU-142721 can also activate rat 
PXR. Based on the structural data presented here, several routes toward the redesign of PNU-
142721 were proposed that may limit PXR activation while keeping intact the HIV-1 RT 
inhibitory activity of this compound.  
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3.5 Figure Legends 
Figure 3.1  Chemical Structures of PNU-142721 and its metabolite PNU-173575 
 
Figure 3.2  Crystal structure of the human PXR-LBD complex with PNU-142721. (A) 
The overall structure of PXR-LBD in complex with PNU-142721. The α-helices, β-strands 
and loops are rendered in cyan, magenta and grey respectively. PNU-142721 is colored by 
elements, with green, red, blue and yellow representing carbon, oxygen, nitrogen and sulfur 
atoms respectively. Note the proximity of the PNU-142721 to αAF of the AF-2 surface of 
PXR. (B) The 2.8 Å simulated annealing omit map contoured at 2.5 σ is shown in blue mesh. 
PNU-142721 is shown and colored by elements. (C) Stereoview of the ligand-binding pocket 
of the PXR-PNU142721compelx. Residues that line the ligand-binding pocket of PXR are 
shown in grey and labeled. The hydrogen bond is represented by a red dash line. 
 
Figure 3.3  Analysis of the ligand binding pocket of PXR-LBD-PNU complex.  
Stereoview of a superimposition between the apo-PXR (blue), PXR-PNU142721 (green) and 
PXR-rifampicin (red) complexes. Major secondary structures around the ligand-binding 
pocket are labeled. The hydrogen bond is represented by a red dash line.  
 
Figure 3.4  Modeled structure of human PXR-LBD in complex with PNU-173575. 
Residues that line PXR-LBD are shown in grey, except for His-407 and Leu-411 which 
undergo rotamer changes in the presence of PNU-173575. The side-chain position of His-407 
and Leu-411 in the presence of PNU-142721 and PNU-173575 are represented in blue and 
magenta respectively.  
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Figure 3.5  Modeled structure of rat PXR-LBD in complex with PNU-142721. Residues 
that line rat PXR-LBD and conserved between human PXR and rat PXR are labeled and 
colored in grey, while residues that are different  between human PXR and rat PXR are 
highlighted in yellow (rat PXR) and magenta (human PXR) respectively 
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3.6 Figures and Tables  
 
Table 3.1 Crystallographic statistics for the PXR-PNU142721 Complex 
 
Resolution (Å) (highest shell) 46-2.8 (2.84-2.80) 
Space group P43212 
Unit Cell dimension (Å) a=b= 92.3, c=84.4 
No. of total reflections 9166 
No. of unique reflections  8944 
Rsym 
a
 (%) (highest shell) 9.4 (53) 
Completeness (%) (highest shell) 99.5 (96.9) 
Mean I/σ (highest shell) 42 (5.1) 
Rcryst  
b
 (%) (highest shell) 23.8 (28) 
Rfree 
c
 (%)  (highest shell) 28.9 (43) 
 
RMSD 
 
Bond lengths (Å) 0.044 
Bond angles ( ⁰ )  3.324 
Dihedral angles ( ⁰ ) 23.6 
Improper angles ( ⁰ ) 3.9 
 
Number of atoms 
 
Protein 2157 
Solvent 16 
Ligand 20 
 
a
 symR I I I    where I is the observed intensity and I is the average intensity of multiple 
symmetry-related observation of the reflection. 
b
 -cryst obs cal obsR F F F    where obsF  and calcF  are the observed and calculated structure 
factors, respectively. 
c -free obs cal obsR F F F    for 10% of the data not used at any stage of the refinement. 
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Figure 3.1   Chemical structures of PNU-142721 and its metabolite PNU-173575 
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Figure 3.2    Crystal structure of the human PXR-LBD complex with PNU-142721 
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Figure 3.3   Analysis of the ligand binding pocket of PXR-LBD-PNU complex 
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Figure 3.4   Modeled structure of human PXR-LBD in complex with PNU-173575 
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Figure 3.5   Modeled structure of rat PXR-LBD in complex with PNU-142721 
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Appendix:  Preliminary studies of the adhesin PilC1 from Neisseria gonorrhoeae 
 
Abstract 
PilC1 is a protein essential for pilus-mediated adherence of Neisseria gonorrhoeae to 
human cells. In this work, we developed a new method for recombinant expression of PilC1 
in E.coli. We identified a calcium binding site in the C-terminal region of PilC1 (residues 
519-1037). Our experiments showed that calcium binding increased the thermostability of 
PilC1, but did not have a significant impact on the secondary structure of PilC1. We also 
examined the role calcium binding plays in the function of PilC1 in vivo. Our results show 
that calcium binding facilitates the surface localization of PilC1. Moreover, calcium binding 
to PilC1 is essential for pilus-mediated adherence of N. gonorrhoeae to human ME180 cells, 
as well as the aggregation of N. gonorrhoeae. Taken together, our results suggest the 
essential role of calcium binding in the normal function of PilC1. 
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Introduction 
N. gonorrhoeae is a species of Gram-negative bacteria which cause a variety of 
human diseases including gonorrhea, conjunctivitis, pharyngitis, proctitis and urethritis. N. 
gonorrhoeae infection starts from the adherence of the bacteria to human epithelial cells, 
which is mediated by the hair-like pili extended from the bacterial surface (123). Following 
the initial attachment, the bacteria use other surface machineries to bind more tightly to and 
invade the epithelial cells (124).      
The pili of N. gonorrhoeae, or the type IV pili, are polymeric structures composed of 
the major pilin (PilE) and a variety of minor pilins, such as PilC, PilV and PilX (125). Type 
IV pili are also found in many other Gram-negative bacteria such as Pseudomonas 
aeruginosa, Dichelobacter nodosus and Vibrio cholera (126). In addition to colonizing host 
cells, type IV pili are essential for many other bacterial activities, such as twitching motility, 
DNA uptake and biofilm formation (127, 128). Disruption of type IV pili is often associated 
with dramatically reduced virulence (129).  
The 110 kDa protein PilC was first identified as a type IV pilus associated adhesin 
(130). Later studies showed that PilC can also be associated with the outer-membrane of the 
bacteria (131). The N-terminal region of PilC mediates the interaction with human cell 
receptors (132). Purified PilC can block the adherence of N. gonorrhoeae to human cells 
(133). PilC is involved in pilus biogenesis and the regulation of pilus retraction (134). Two 
copies of PilC genes, PilC1 and PilC2, are present in the genome of N. gonorrhoeae. The 
protein PilC1 and PilC2 are very similar in sequence and functionally interchangeable (132). 
Several lines of evidence have suggested that the initial adherence of N. gonorrhoeae to 
human cells is mediated by the human cell receptor CD46 (135, 136). However, some studies 
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indicated that CD46 may not be essential for the initial attachment of N. gonorrhoeae and 
PilC to human cells (137).  
The yield of PilC from current methods is too low to meet the requirement of 
extensive in vitro studies. In this work, we have developed a new expression and purification 
method that is significantly more efficient than previous methods. In addition, we identified a 
calcium binding site in the C-terminal region of PilC1 and examined the role of calcium 
binding in the structure and function of PilC1.    
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Materials and methods 
Protein constructs, expression and purification  
Standard ligation independent cloning techniques, as described by Stols et al. (20), 
were employed in the construction of expression plasmids encoding the segments of PilC1 
used in this study. The amplified DNA fragments were treated and cloned into empty 
pMCSG7-Lic-His expression vector. All expression plasmids used in this study were 
sequence verified. 
The expression plasmids were transformed into E.coli BL21(DE3)Origami 2 
(Stratagene). Bacteria were grown in LB medium supplemented with ampicillin, 
streptomycin and tetracycline at 37 
o
C with shaking. After the OD600 reached 0.6, isopropyl 
β-D-thiogalactoside was added to a final concentration of 0.2 mM and bacteria were grown 
for another 12 hours at 16 
o
C with shaking.  Bacteria were harvested and resuspended in 
loading buffer (50 mM sodium phosphate pH 7.6, 500 mM NaCl, 25 mM imidazole) 
supplemented with 0.5 mM EDTA, 0.1% Triton X-100, 1 mM PMSF, one tablet of a 
protease inhibitor cocktail (Roche) and 1 mg/ml lysozyme. After 1 hour of incubation on ice, 
the resuspended cells were sonicated on ice for 2 min and the lysate was centrifuged at 
45,000 × g for 90 min at 4 
oC. The supernatant was passed through a 0.2 μm filter (Millipore) 
and then loaded onto a 5 ml high performance HisTrap
TM
 column (GE Life Sciences), 
equilibrated with loading buffer. The column was washed with 100 ml loading buffer before 
bound protein was eluted with elution buffer (50 mM sodium phosphate pH 7.6, 500 mM 
NaCl, 500 mM imidazole). The eluted protein was concentrated and loaded on a HiLoad
TM
 
16/60 Superdex 200 column (GE Life Sciences) equilibrated with sizing buffer (20 mM Tris-
HCl pH 7.5, 250 mM NaCl, 2 mM DTT, 5% Glycerol). Protein containing fractions were 
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concentrated, flash frozen in liquid nitrogen and stored at -80 
o
C.  Purified protein was >95% 
pure by SDS-PAGE.  
Calcium binding assay 
Terbium ion was used as a substitute of calcium ion due to their similar properties 
(ionic radius and coordination properties). More importantly, terbium can be excited by 
tryptophan emission and produce an emission at a certain wavelength. Terbium binding to 
protein, then, can be quantified by measuring its specific emission. FRET experiment was 
carried out at 25
 o
C using a SPEX Fluorolog-3 Research T-format Spectrofluorometer 
(Horiba Jobin Yvon, Edison, NJ). Terbium chloride was diluted in protein buffer (20 mM 
Tris-HCl, ph7.5, 250 mM NaCl) to a working concentration of 10 mM. Protein (400 μl at 0.2 
mg/ml) was added to the cuvette, and terbium chloride was added in 0.2 μl increments. The 
tryptophan residues in protein were excited at 283 nm, and terbium fluorescence emission 
was recorded at 543 nm. The error bars represent the standard deviation of three replicates. 
The data was fitted to a one-site binding equation and the dissociation constant is determined 
to be 0.9 ±0.2 μM.  
Circular Dichroism spectroscopy 
Far-UV CD spectra of PilC1 were measured with a JASCS J715 CD 
spectropolarimeter for the 205-260 nm using a 1 mm path-length cell region at 22 
o
C. 
Thermal denaturation of PilC1 was analyzed by monitoring ellipticity changes at the 
wavelength of 222 nn while the sample was heated at a constant rate of 2 min/
 o
C.  The basic 
protein buffer contained 20 mM Tris-HCl, ph7.5 and 250 mM NaCl.    
Cell lines and growth conditions 
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The ME180 cells were grown in McCoy’s 5A medium supplemented with 10% fetal 
bovine serum (FBS) at 37
 o
C, 5% CO2. N. gonorrhoeae strains were grown on GCB-agar 
plates, containing Kellogg’s supplement (138) at 37 oC in 5% CO2. 
Cell adherence assay 
The experiment was performed as previously described (137) but employed the 
human epithelial ME180 cell line. ME180 cells were incubated with N. gonorrhoeae strain 
FA1090. After one hour, ME180 cells were washed three times with medium and lysed with 
1% saponin. The colony forming units were quantified by plating serial dilutions of cell 
lyses. The assay was performed in triplicate. The error bars represent the standard error of the 
normalized fraction of GC adherence. To examine the impact of recombinant PilC1 on the 
adherence of GC to human cells, ME180 cells were pre-incubated with different 
concentrations of PilC1 or BAS for 30 min before the incubation with N. gonorrhoeae strain 
FA1090. The adherence of GC to ME180 cells was inhibited in a dose-dependent manner by 
full-length PilC1 protein (residues 23-1037), but not by PilC1-CTD (residues 519-1037) and 
BSA. 
Cell surface exposure assay 
Purified PilC1 specific monoclonal antibodies, 4B5.10 and 1D5, are biotinylated with 
NHS-PEO4-Biotin. They were incubated with Neisseria gonorrhoeae strain FA1090 for 30 
min and the antibodies bound to the GC surface were detected by binding of HRP-
streptavidin. HRP was then detected by production of light in the presence of 
chemiluminescent substrate. All experiments were done in triplicate.   
Aggregation of N. gonorrhoeae 
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N. gonorrhoeae strains were grown at 37
 o
C overnight on GCB-agar plate. Bacteria 
were scraped off and resuspended in PBS buffer to OD600 ≈1. The suspension was kept at 
room temperature and the OD600 of the supernatant was measured at different time-points.  
Results and Discussion 
To identify the PilC1 constructs that can be expressed as soluble proteins in E.coli, 
we test-expressed a series of PilC1 constructs in E.coli cell lines (Table 1). Our results show 
that only full-length (FL) PilC1 (residues 23-1037) and the C-terminal domain (CTD) of 
PilC1 (residues 519-1037) can be expressed as soluble proteins in E.coli BL21 (DE3) 
Origami 2. As indicated by SDS-PAGE, the purity of purified FL-PilC1 and PilC-CTD was 
over 95% (Figure 1). The expression level of PilC1-CTD is considerably higher than that of 
FL-PilC1. Accordingly, these two PilC1 constructs were used in the following in vitro 
studies of PilC1.  
Previous studies showed that purified FL-PilC can block the adherence of N. 
gonorrhoeae to human cells by competing with pilus-associated native PilC (133). Here, we 
examined the impact of the recombinant FL-PilC1 obtained in this study on the adherence of 
N. gonorrhoeae strain FA1090 to human ME180 cells. As shown in Figure 2, FL-PilC1 
inhibited the adherence in a dose-dependent manner with an IC50 of about 10 nM. As 
expected, bovine serum albumin that does not specifically interact with human cells did not 
have a significant effect on the adherence. Taken together, our results suggest that the 
recombinant FL-PilC1 obtained in this study is likely well folded. Our results also showed 
that PilC1-CTD did not affect the adherence of GC to human ME180 cells, which is 
consistent with the previous observation that the N-terminal region of PilC is responsible for 
the interaction with human receptors (132).       
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Recent studies from our lab identified a calcium binding site in the PilY1 protein 
from Pseudomonas aeruginosa that shares high homology with the PilC protein from N. 
gonorrhoeae (139). The result from sequence alignment suggested that PilC1 may also have 
a calcium binding site in its C-terminal domain (Figure 3). Calcium binding experiments 
showed that PilC1-CTD can bind calcium in a manner that can be fitted with a one-site 
binding model (Kd = 0.9 ± 0.2 µM) (Figure 4). Moreover, the aspartic residues (D731A, 
D733A and D739A) in the calcium binding site are essential for calcium binding as 
suggested by the fact that mutation of any of them could abolish the binding of calcium to 
PilC1 (Figure 4).   
The impact of calcium binding on the secondary structure of PilC1-CTD was 
examined by Circular Dichroism (CD) spectroscopy. Our results clearly showed that the 
presence of calcium did not cause significant change in the CD profile of PilC1-CTD in the 
far-UV region, suggesting that calcium binding does not affect the secondary structure of 
PilC1-CTD (Figure 5). We also examined the impact of calcium binding on the 
thermostability of PilC1-CTD. The presence of calcium shifted the thermodenaturation curve 
to higher temperature, increasing the melting temperature (Tm) for about 5 
o
C. This 
observation indicates that calcium binding increases the thermostability of PilC1-CTD.  
To examine the role calcium binding plays in the function of PilC1 in vivo, we 
engineered several N. gonorrhoeae strains, in which the wide-type PilC1 gene was 
substituted with PilC1 genes that carry different calcium binding site mutations. We first 
examined the expression of PilC1 mutants in engineered N. gonorrhoeae strains. Western-
blot analysis showed that PilC1-D731A had wide-type level expression, while PilC1-D733A 
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and PilC1-D739A had significantly reduced expression (Figure 7). As a result, only PilC1-
D731A was used in the following analysis. 
 We next investigated the exposure of PilC1 mutants on the surface of N. 
gonorrhoeae (see materials and methods for details). The monoclonal antibody 4B5.10 can 
recognize pilus-associated and outer-membrane associated PilC1, while 1D5 can only 
recognize pilus-associated PilC1. The non-piliated N. gonorrhoeae strain (PilC1
+
/PilC2
-
/PilE
-
) was used as a negative control here. Our results showed that the amount of PilC1-
D731A on type IV pili or the bacterial surface as a whole was significantly less than that of 
wide-type PilC1 (Figure 8), suggesting that calcium binding promotes the surface exposure 
of PilC1. In addition, the N. gonorrhoeae strain expressing PilC1-D731A (PilC1-
D731A
+
/PilC2
-
) exhibited dramatically reduced adherence to human ME180 cells compared 
to the N. gonorrhoeae strain expressing wide-type PilC1 (PilC1-D731A
+
/PilC2
-
) (Figure 8).   
Finally, we examined the aggregation of the N. gonorrhoeae that is mainly mediated 
by type IV pili. As expected, the hyperpiliated N. gonorrhoeae strain (PilC1
+
PilC2
-
/PilT
-
) 
displayed higher levels of aggregation than the piliated strain (PilC1
+
/PilC2
-
), and the non-
piliated strain (PilC1
+
/PilC2
-
/PilE
-
) displayed the lowest level of aggregation (Figure 9). 
Interestingly, the GC strain expressing PilC1-D731A (PilC1-D731A
+
/PilC2
-
) displayed 
similar levels of aggregation with the non-piliated GC strain, suggesting that the N. 
gonorrhoeae strain expressing PilC1-D731A may have some defects in pilus biogenesis.  
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Figure lengends 
Figure 1. SDS-PAGE of purified PilC1 constructs.  (A) The C-terminal domain (CTD) of 
PilC1 (residues 519-1037). (B) Full-length (FL) PilC1 (residues 23-1037). M represents the 
protein marker. 12% SDS-PAGE were used here. 
Figure 2. Purified full-length PilC1 protein inhibits in a dose-dependent manner the 
adherence of Neisseria gonorrhoeae to human epithelial cells. ME180 cells were 
preincubated with increasing concentrations of PilC1 proteins or Bovine Serum Albumin 
(BSA) for 30 minutes before being washed and incubated with GC strain FA1090 in our cell 
adherence assay. The assay was performed in triplicate on three days. The error bars 
represent the standard error of the normalized fraction of GC adherence.  
Figure 3. Partial sequence alignment of Pseudomonas aeruginosa PilY1 and PilC from 
various Neisseria species. The residues involved in calcium ion binding in PilY1 are 
denoted by asterisks and labeled. Sequence conservation is highlighted in red.   
Figure 4. Binding of Tb
3+ 
to different PilC1 constructs. Different PilC1-CTD constructs 
were titrated with increasing concentrations of TbCl3 as described in our materials and 
methods. The solid line is computer fit of the data using one-site binding model.  
Figure 5. Impact of calcium binding on the secondary structure of PilC1.  The far-UV 
CD spectra of PilC1-CTD in the absence or presence of CaCl2 were recorded as described in 
the materials and methods.  
Figure 6. Impact of calcium binding on the thermostability of PilC1. The change of 
ellipticity at 222 nm with the increase of temperature was recorded as described in the 
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materials and methods. The melting temperature (Tm) indicates the temperature that the 
protein loses half of its ellipticity at 222 nm.   
Figure 7. Expression of PilC1 calcium binding mutants in Neisseria gonorrhoeae. 
Western-blot of the whole cell lysates of GC strains expressing different PilC constructs are 
shown here. N represents the GC strain that does not express PilC.   
Figure 8. Impact of calcium binding on the surface exposure of PilC1 and the adherence 
of Neisseria gonorrhoeae to human ME180 cells. The surface exposure of PilC1 proteins 
and the adherence of different GC strains to human ME180 cells were performed as 
described in the materials and methods. The experiments were performed in triplicate on 
three days. The error bars represent the standard error of the normalized fraction of surface 
exposure or GC adherence.  
Figure 9. Impact of calcium binding on aggregation of Neisseria gonorrhea. The OD600 of 
the supernatant of the solutions that contain different GC strains were measured at different 
time-points.    
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Table 1.  Expression of pilC1 constructs in various E.coli cell lines. The sign ―–‖insoluble 
expression.  The sign ―+/-‖ indicates that the protein is soluble in the presence of the maltose 
binding protein (MBP) tag, but is insoluble after the removal of the MBP tag. The expression 
level is qualitatively reflected by the number of ―+‖.  
 
Protein Constructs 
BL21 (DE3) Gold & pLysS & RIPL BL21(DE3) Origami 2 
Lic-his Lic-MBP-his Lic-his Lic-MBP-his 
Full-length     
23-1037 - - + - 
C-terminal domain     
519-974 - +/ - +/ 
519-982 - +/ - +/ 
519-984 - +/ - +/ 
519-986 - +/ - +/ 
519-1014 - +/ - +/ 
519-1037 - +/ ++++ +/ 
492-1037 - +/ - +/ 
513-1037 - +/ - +/ 
572-1037 - +/ - +/ 
592-1037 - +/ - +/ 
602-1037 - +/ - +/ 
N-terminal domain     
23-485 - - - - 
119-485 - - - - 
180-485 - - - - 
224-485 - - - - 
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Figure 1. SDS-PAGE of purified PilC1 constructs 
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Figure 2. Purified full-length PilC1 protein inhibits in a dose-dependent manner the 
adherence of Neisseria gonorrhoeae to human epithelial cells 
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Figure 3. Partial sequence alignment of Pseudomonas aeruginosa PilY1 and PilC from 
various Neisseria species 
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Figure 4. Binding of Tb
3+ 
to different PilC1 constructs 
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Figure 5. Impact of calcium binding on the secondary structure of PilC1 
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Figure 6. Impact of calcium binding on the thermostability of PilC1 
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Figure 7. Expression of PilC1 calcium binding mutants in Neisseria gonorrhoeae 
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Figure 8.  Impact of calcium binding on the surface exposure of PilC1 and the 
adherence of Neisseria gonorrhoeae to human ME180 cells 
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Figure 9.  Impact of calcium binding on aggregation of Neisseria gonorrhoeae 
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